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S2 
 
General 
 
All chemicals were purchased from commercial sources and used without further 
puriﬁcation unless otherwise noted. THF, CH2Cl2, and DMF were purified via Innovative 
Technology's Pure-Solve System. All reactions were performed under an Argon 
atmosphere. All stirring was performed with an internal magnetic stirrer. Reactions were 
monitored by TLC using 0.25 mm coated commercial silica gel plates (EMD, Silica Gel 
60F254). TLC spots were visualized by UV light at 254 nm, or developed with ceric 
ammonium molybdate or anisaldehyde or copper sulfate or ninhydrin solutions by 
heating on a hot plate. Reactions were also monitored by using SHIMADZU LCMS-2020 
with solvents: A: 0.1% formic acid in water, B: acetonitrile. Flash chromatography was 
performed with SiliCycle silica gel (Purasil 60 Å, 230-400 Mesh). Proton magnetic 
resonance (
1
H-NMR) spectral data were recorded on 400, and 500 MHz instruments. 
Carbon magnetic resonance (
13
C-NMR) spectral data were recorded on 100 and 125 MHz 
instruments. For all NMR spectra, chemical shifts (δH, δC) were quoted in parts per 
million (ppm), and J values were quoted in Hz. 
1
H and 
13
C NMR spectra were calibrated 
with residual undeuterated solvent (CDCl3: δH = 7.26 ppm, δC = 77.16 ppm; CD3CN: δH 
= 1.94 ppm, δC = 1.32ppm; CD3OD: δH =3.31 ppm, δC =49.00 ppm;  DMSO-d6: δH = 
2.50 ppm, δC = 39.52 ppm; D2O: δH = 4.79 ppm) as an internal reference. The following 
abbreviations were used to designate the multiplicities: s = singlet, d = doublet, dd = 
double doublets, t = triplet, q = quartet, quin = quintet, hept = heptet, m = multiplet, br = 
broad. Infrared (IR) spectra were recorded on a Perkin-Elmer FT1600 spectrometer. 
HPLC analyses were performed with a Shimadzu LC-20AD HPLC system. HR-MS data 
were obtained from a Waters Synapt G2-Si (ion mobility mass spectrometer with 
nanoelectrospray ionization). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S3 
 
O
HO OH
STolTrO
S1  
 
(2S,5R)-2-(p-Tolylthio)-5-((trityloxy)methyl)tetrahydrofuran-3,4-diol (S1). The title 
compound was synthesized according to the reported procedure 
1
: TLC (hexanes/EtOAc 
50:50) Rf = 0.50; []
21
D -1.029 (c = 1.42, CHCl3); IR (thin film) max = 3395 (br), 3058, 3021, 
2921, 2870, 1491, 1448, 1216, 1075, 1012, 745, 698 cm
−1
; 
1
H NMR (400 MHz, CDCl3) δ 7.46 (d, 
J = 7.3 Hz, 6H), 7.41 (d, J = 7.9 Hz, 2H), 7.32 – 7.21 (m, 9H), 7.07 (d, J = 7.8 Hz, 2H), 5.22 (d, J 
= 4.9 Hz, 1H), 4.16 (q, J = 4.7 Hz, 1H), 4.08 (dq, J = 12.9, 4.7 Hz, 2H), 3.26 (qd, J = 10.0, 4.4 
Hz, 2H), 2.59 (d, J = 4.7 Hz, 1H), 2.41 (d, J = 4.0 Hz, 1H), 2.31 (s, 3H); 
13
C NMR (101 MHz, 
CDCl3) δ 143.7 (2C), 137.8, 132.8 (3C), 129.7 (2C), 129.4, 128.7 (6C), 127.9 (6C), 127.1 (3C), 
90.5, 87.0, 83.4, 75.3, 72.5, 64.2, 21.1; HRMS (ESI+) m/z calcd for C31H30O4NaS [M + Na] 
521.1762, found: 521.1741. 
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3,3-Dimethyl-5-((triisopropylsilyl)oxy)pentanoic acid (S2). The title compound was 
synthesized according to the reported procedure 
1
: TLC (hexanes/EtOAc 50:50) Rf = 0.50; IR 
(thin film) max = 2942, 2866, 1705, 1463, 1246, 1097, 996, 881, 738, 678 cm
−1
; 
1
H NMR (400 
MHz, CDCl3) δ 3.88 (t, J = 5.8 Hz, 2H), 2.38 (s, 2H), 1.71 (t, J = 5.8 Hz, 2H), 1.20 – 1.11 (m, 
3H), 1.09 (s, 12H), 1.08 (s, 6H), 1.07 (s, 6H); 
13
C NMR (101 MHz, CDCl3) δ 173. 9, 60.7, 46.8, 
42.6, 32.4, 28.5 (2C), 17.9 (6C), 11.8 (3C); HRMS (ESI+) m/z calcd for C16H34O3NaSi [M + Na] 
325.2175, found 325.2171. 
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 (2S,5R)-2-(p-Tolylthio)-5-((trityloxy)methyl)tetrahydrofuran-3,4-diyl bis(3,3-
dimethyl-5-((triisopropylsilyl)oxy)pentanoate) (S3). To a stirred solution of S1 (2.03 g, 
4.07 mmol) and S2 (2.71 g, 8.96 mmol) in CH2Cl2 (20 mL) were added DMAP (1.24 g, 
10.18 mmol) and DIC (1.59 mL, 10.18 mmol) at 0 
o
C. The reaction mixture was stirred 
for 15 h at rt and concentrated in vacuo. The crude mixture was purified by silica gel 
column chromatography (hexanes/EtOAc 99:1 to 98:2) to afford S3 (4.23 g, 3.96 mmol, 
97%): TLC (hexanes/EtOAc 90:10) Rf = 0.60; []
21
D -0.693 (c = 2.70, CHCl3); IR (thin film) max 
= 2941, 2865, 1743, 1463, 1219, 1099, 1013, 999, 882, 745, 704, 681 cm
−1
; 
1
H NMR (400 MHz, 
CDCl3) δ 7.47 (d, J = 7.2 Hz, 6H), 7.41 (d, J = 7.9 Hz, 2H), 7.29 (t, J = 7.5 Hz, 6H), 7.23 (q, J = 
7.1 Hz, 3H), 7.06 (d, J = 7.8 Hz, 2H), 5.40 – 5.35 (m, 2H), 5.33 (d, J = 5.0 Hz, 1H), 4.18 (q, J = 
4.1 Hz, 1H), 3.78 (t, J = 7.1 Hz, 2H), 3.73 (t, J = 6.9 Hz, 2H), 3.22 (dd, J = 10.3, 4.1 Hz, 1H), 
3.13 (dd, J = 10.3, 4.6 Hz, 1H), 2.30 (s, 3H), 2.27 (d, J = 13.8 Hz, 2H), 2.22 (s, 2H), 1.65 (t, J = 
6.9 Hz, 2H), 1.56 (t, J = 6.9 Hz, 2H), 1.12 – 1.01 (m, 48H), 0.97 (d, J = 5.5 Hz, 6H); 13C NMR 
 
S4 
 
(101 MHz, CDCl3) δ 170.7, 170.5, 143.6 (2C), 138.0, 133.3 (2C), 129.7 (3C), 128.9, 128.8 (6C), 
127.8 (6C), 127.0 (3C), 88.3, 86.9, 82.2, 73.6, 71.6, 63.6, 60.04, 59.98, 46.2, 46.1, 44.74, 44.71, 
32.7, 32.5, 27.51, 27.48, 27.4, 22.7, 21.1, 18.07 (6C), 18.05 (6C), 11.94 (3C), 11.91 (3C); HRMS 
(ESI+) m/z calcd for C63H94NaO8SSi2 [M + Na] 1089.6106, found: 1089.6098. 
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(2R,5S)-2-(Hydroxymethyl)-5-(p-tolylthio)tetrahydrofuran-3,4-diyl bis(3,3-dimethyl-
5-((triisopropylsilyl)oxy)pentanoate) (S4). To a stirred solution of S3 (4.23 g, 3.96 
mmol) and thiocresol (0.98 g, 7.92 mmol) in CH2Cl2 (20 mL) was added BF3
.
OEt2 (0.20 
mL, 1.58 mmol) at 0 
o
C. After being stirred for 1.5 h, the reaction was quenched with aq. 
saturated NaHCO3 and extracted with EtOAc. The combined organic solution was dried 
over Na2SO4 and concentrated in vacuo. The crude mixture was purified by silica gel 
column chromatography (hexanes/EtOAc 90:10 to 80:20) to afford S4 (1.81 g, 2.19 
mmol, 55%): TLC (hexanes/EtOAc 90:10) Rf = 0.20; []
21
D -1.733 (c = 3.98, CHCl3); IR (thin 
film) max = 3474 (br), 2941, 2891, 2866, 2724, 1743, 1493, 1464, 1389, 1367, 1326, 1250, 1219, 
1190, 1099, 1070, 1054, 1013, 999, 882, 809, 772, 741, 681 cm
−1
; 
1
H NMR (400 MHz, CDCl3) δ 
7.42 (d, J = 7.8 Hz, 2H), 7.15 (d, J = 7.8 Hz, 2H), 5.26 (d, J = 5.4 Hz, 1H), 5.23 (t, J = 4.8 Hz, 
1H), 5.19 (t, J = 5.3 Hz, 1H), 4.11 (q, J = 3.7 Hz, 1H), 3.81 – 3.73 (m, 4H), 3.72 (d, J = 3.2 Hz, 
1H), 3.59 (dd, J = 12.4, 3.6 Hz, 1H), 2.34 (s, 3H), 2.31 (d, J = 8.7 Hz, 2H), 2.27 (d, J = 5.5 Hz, 
2H), 1.63 (t, J = 7.5 Hz, 2H), 1.59 (t, J = 6.9 Hz, 2H), 1.05 (q, J = 4.8, 3.7 Hz, 54H); 
13
C NMR 
(101 MHz, CDCl3) δ 171.11, 170.51, 138.81, 133.89 (2C), 129.89 (2C), 127.66, 88.06, 83.80, 
73.71, 71.26, 62.16, 60.02, 59.99, 46.18, 46.11, 44.65, 44.56, 32.67, 32.61, 27.52, 27.48, 27.42, 
21.16, 18.05 (6C), 18.04 (6C), 11.92 (3C), 11.91 (3C); HRMS (ESI+) m/z calcd for 
C44H80NaO8SSi2 [M + Na] 847.5010, found: 847.5023. 
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(2R,5S)-2-(Azidomethyl)-5-(p-tolylthio)tetrahydrofuran-3,4-diyl bis(3,3-dimethyl-5-
((triisopropylsilyl)oxy)pentanoate) (15). To a stirred solution of S4 (1.81 g, 2.19 mmol) 
and PPh3 (1.15 g, 4.38 mmol) in dry benzene (5 mL) were added HN3 (0.6 M in benzene, 
36.5 mL, 21.9 mmol) and DIAD (0.86 mL, 4.38 mmol). The reaction mixture was stirred 
for 24 h at rt and concentrated in vacuo. The crude mixture was purified by silica gel 
column chromatography (hexanes/EtOAc 95:5) to afford 15 (1.71 g, 2.01 mmol, 92%): 
TLC (hexanes/EtOAc 90:10) Rf = 0.60; []
21
D -0.293 (c = 1.39, CHCl3); IR (thin film) max = 
2792, 2892, 2866, 2102, 1745, 1464, 1390, 1367, 1282, 1254, 1219, 1190, 1100, 1071, 1054, 
1013, 998, 882, 809, 772, 742, 681 cm
−1
; 
1
H NMR (400 MHz, CDCl3) δ 7.43 (d, J = 8.1 Hz, 2H), 
7.14 (d, J = 7.9 Hz, 2H), 5.26 (d, J = 5.3 Hz, 1H), 5.18 (t, J = 5.3 Hz, 1H), 5.11 (t, J = 5.0 Hz, 
1H), 4.13 (q, J = 4.7 Hz, 1H), 3.76 (dt, J = 10.6, 6.9 Hz, 4H), 3.42 (d, J = 4.7 Hz, 2H), 2.34 (s, 
 
S5 
 
3H), 2.31 (d, J = 10.6 Hz, 2H), 2.26 (d, J = 4.9 Hz, 2H), 1.61 (dtd, J = 17.4, 6.9, 2.1 Hz, 4H), 1.08 
– 1.00 (m, 54H); 13C NMR (101 MHz, CDCl3) δ 170.91, 170.54, 138.67, 133.89 (2C), 129.81 
(2C), 127.88, 88.58, 81.48, 73.52, 71.70, 60.02, 59.97, 52.70, 46.15, 46.03, 44.64, 44.55, 32.68, 
32.60, 27.51, 27.47, 27.38, 21.17, 18.06 (6C), 18.05 (6C), 11.93 (3C), 11.92 (3C); HRMS (ESI+) 
m/z calcd for C44H79N3NaO7SSi2 [M + Na] 872.5075, found: 872.5088. 
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3-(((2,6-Dichloro-4-methoxyphenyl)(2,4-dichlorophenyl)methoxy)methyl)-1-
((3aR,4R,6R,6aR)-6-((S)-1-hydroxy-5-phenylpent-2-yn-1-yl)-2,2-
dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)pyrimidine-2,4(1H,3H)-dione (14). 
Title compound was synthesized according to the reported procedure 
1
: TLC 
(hexanes/EtOAc 50:50) Rf = 0.30; []
22
D -0.116 (c = 2.17, CHCl3); IR (thin film) max = 3387 (br), 
2981, 2937, 1664, 1454, 1276, 1065, 1039, 856, 733, 698 cm
−1
; 
1
H NMR (400 MHz, CDCl3) δ 
7.53 (ddd, J = 20.4, 8.5, 0.7 Hz, 1H), 7.35 – 7.27 (m, 4H), 7.24 – 7.15 (m, 4H), 6.85 (d, J = 5.1 
Hz, 2H), 6.51 (d, J = 5.4 Hz, 1H), 5.68 (dd, J = 8.1, 4.1 Hz, 1H), 5.60 – 5.50 (m, 3H), 4.89 – 4.78 
(m, 2H), 4.57 (ddt, J = 12.0, 4.3, 2.0 Hz, 1H), 4.24 (dd, J = 4.4, 3.1 Hz, 1H), 3.78 (d, J = 3.3 Hz, 
3H), 2.83 (t, J = 7.5 Hz, 2H), 2.53 (td, J = 7.4, 2.0 Hz, 2H), 1.57 (s, 3H), 1.36 (s, 3H); 
13
C NMR 
(101 MHz, CDCl3) δ 162.11, 162.08, 159.5, 150.87, 150.85, 141.1, 140.8, 140.30, 140.27, 136.9, 
135.4, 135.3, 133.99, 133.95, 133.8, 133.6, 131.2, 129.4, 129.3, 128.41, 128.39, 126.4, 126.21, 
126.18, 125.5, 125.4, 115.34, 115.32, 114.3, 114.2, 101.8, 101.7, 96.7, 96.4, 89.23, 89.19, 86.8, 
86.7, 84.1, 84.0, 80.9, 69.5, 63.02, 62.99, 55.7, 34.72, 34.70, 27.2, 25.3, 20.87, 20.85; HRMS 
(ESI+) m/z calcd for C37H34N2O8NaCl4 [M + Na] 797.0967, found: 797.0994. 
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Figure S1. Determination of the stereochemistry of 14
2
 via the advanced Mosher 
method.
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(2R,3R,4R,5R)-2-(Azidomethyl)-5-(((1S)-1-((3aR,4R,6R,6aR)-6-(3-(((2,6-dichloro-4-
methoxyphenyl)(2,4-dichlorophenyl)methoxy)methyl)-2,4-dioxo-3,4-
dihydropyrimidin-1(2H)-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-5-
phenylpent-2-yn-1-yl)oxy)tetrahydrofuran-3,4-diyl bis(3,3-dimethyl-5-
((triisopropylsilyl)oxy)pentanoate) (16). To a stirred suspension of 14 (227 mg, 0.292 
mmol), 15 (497 mg, 0.584 mmol), MS3A (900 mg) and SrCO3 (431 mg, 2.920 mmol) in 
CH2Cl2 (12.0 mL) were added AgBF4 (28.5 mg, 0.146 mmol) and NIS (131 mg, 0.584 
mmol) at 0 
o
C. After 24 h, the reaction mixture was added Et3N (2 mL) and passed 
through a silica gel pad (hexanes/EtOAc 1:1). The combined organic phase was 
concentrated in vacuo. The crude mixture was purified by silica gel column 
chromatography (hexanes/EtOAc 90:10 to 80:20 to 70:30) to afford 16 (416 mg, 0.277 
mmol, 95%): TLC (hexanes/EtOAc 67:33) Rf = 0.70; []
21
D +0.100 (c = 2.09, CHCl3); IR (thin 
film) max = 2942, 2866, 2102, 1743, 1724, 1675, 1456, 1278, 1218, 1099, 1070, 882, 772 cm
−1
; 
1
H NMR (400 MHz, CDCl3) δ 7.54 (dd, J = 23.1, 8.5 Hz, 1H), 7.32 – 7.27 (m, 4H), 7.24 – 7.16 
(m, 4H), 6.84 (d, J = 7.3 Hz, 2H), 6.51 (d, J = 3.7 Hz, 1H), 5.71 – 5.64 (m, 2H), 5.60 – 5.49 (m, 
2H), 5.20 – 5.16 (m, 3H), 4.79 (ddd, J = 7.5, 6.5, 3.1 Hz, 1H), 4.64 (td, J = 5.9, 2.6 Hz, 1H), 4.57 
(ddt, J = 11.4, 6.3, 1.9 Hz, 1H), 4.28 (dt, J = 6.2, 2.8 Hz, 1H), 4.19 (tt, J = 6.1, 3.0 Hz, 1H), 3.79 
– 3.72 (m, 7H), 3.50 (ddd, J = 13.0, 7.6, 3.3 Hz, 1H), 3.35 (dd, J = 13.0, 3.4 Hz, 1H), 2.83 (t, J = 
7.4 Hz, 2H), 2.55 (td, J = 7.4, 1.8 Hz, 2H), 2.29 (t, J = 1.6 Hz, 2H), 2.24 (dd, J = 5.1, 2.1 Hz, 2H), 
1.62 – 1.55 (m, 7H), 1.36 (d, J = 2.0 Hz, 3H), 1.08 – 1.00 (m, 54H); 13C NMR (101 MHz, CDCl3) 
δ 175.6, 171.0, 170.9, 170.71, 170.70, 170.6, 162.2, 162.1, 159.5, 150.8, 150.7, 140.4, 140.19, 
140.15, 140.13, 136.92, 136.91, 135.4, 135.3, 133.9, 133.8, 133.7, 131.2, 129.4, 129.3, 128.5 
(2C), 128.4 (2C), 126.5, 126.4, 126.2, 126.1, 125.6, 125.5, 115.29, 115.25, 114.23, 114.22, 
104.61, 104.55, 101.83, 101.82, 88.8, 88.2, 84.44, 84.35, 83.9, 81.4, 81.3, 80.6, 79.9, 76.5, 75.9, 
75.8, 74.1, 71.8, 71.7, 71.4, 70.7, 69.6, 69.5, 68.9, 68.8, 59.97, 59.96, 55.7, 46.2, 46.0, 44.7, 44.6, 
34.7, 34.51, 34.49, 32.7, 32.61, 32.57, 28.0, 27.38, 27.35, 27.3, 27.1, 25.34, 25.27, 20.9, 18.1 
(12C), 11.9 (6C); HRMS (ESI+) m/z calcd for C74H106Cl4N5O15Si2 [M + H] 1500.5978, found: 
1500.5992. 
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(2R,3R,4R,5R)-2-(((tert-Butoxycarbonyl)amino)methyl)-5-(((1S)-1-((3aR,4R,6R,6aR)-
6-(3-(((2,6-dichloro-4-methoxyphenyl)(2,4-dichlorophenyl)methoxy)methyl)-2,4-
dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-
4-yl)-5-phenylpent-2-yn-1-yl)oxy)tetrahydrofuran-3,4-diyl bis(3,3-dimethyl-5-
((triisopropylsilyl)oxy)pentanoate) (17). A suspended solution of 16 (286 mg, 0.19 
mmol), NH4Cl (305 mg, 5.70 mmol) and Zn (373 mg, 5.70 mmol) in EtOH/H2O (9:1, 9.5 
mL) was stirred at 80 
o
C for 12 h and cooled to rt. The precipitates were filtered and the 
combined organic solution was concentrated in vacuo. The crude mixture was used for 
the next reaction without purification. To a stirred solution of crude mixture in THF (9.5 
mL) were added saturated NaHCO3 (aq., 9.5 mL) and Boc2O (124 mg, 0.57 mmol). The 
reaction mixture was stirred for 6 h at rt, and the aqueous layer was extracted with EtOAc. 
The combined organic extracts were dried over Na2SO4 and concentrated in vacuo. The 
crude mixture was purified by silica gel column chromatography (hexanes/EtOAc 85:15 
to 80:20 to 67:33) to afford 17 (258 mg, 0.16 mmol, 86% for 2 steps): TLC 
(hexanes/EtOAc 70:30) Rf = 0.30; []
21
D +0.012 (c = 0.90, CHCl3); IR (thin film) max = 2941, 
2866, 1720, 1676, 1456, 1366, 1278, 1219, 1100, 1070, 882, 772 cm
−1
;  1H NMR (400 MHz, 
CDCl3) δ 7.54 (dd, J = 19.9, 8.5 Hz, 1H), 7.33 – 7.27 (m, 4H), 7.24 – 7.16 (m, 4H), 6.85 (d, J = 
7.3 Hz, 2H), 6.51 (d, J = 4.8 Hz, 1H), 5.72 – 5.64 (m, 2H), 5.60 – 5.48 (m, 2H), 5.26 (d, J = 6.0 
Hz, 1H), 5.17 (d, J = 8.6 Hz, 2H), 5.13 – 5.08 (m, 1H), 4.82 – 4.76 (m, 1H), 4.65 (t, J = 7.0 Hz, 
1H), 4.51 (dd, J = 13.8, 6.0 Hz, 1H), 4.31 – 4.26 (m, 1H), 4.23 – 4.17 (m, 1H), 3.78 (d, J = 2.7 Hz, 
3H), 3.74 (d, J = 6.9 Hz, 4H), 3.48 – 3.40 (m, 1H), 3.36 – 3.26 (m, 1H), 2.83 (t, J = 7.4 Hz, 2H), 
2.56 (t, J = 7.5 Hz, 2H), 2.27 (t, J = 2.6 Hz, 2H), 2.23 (t, J = 3.0 Hz, 2H), 1.62 – 1.55 (m, 7H), 
1.42 (s, 9H), 1.37 (d, J = 2.6 Hz, 3H), 1.11 – 0.99 (m, 54H); 13C NMR (101 MHz, CDCl3) δ 159.5, 
150.8, 136.9, 131.3, 129.3, 128.5 (2C), 128.4 (2C), 126.5, 126.1, 125.4, 115.30, 115.26, 80.0, 
60.0, 55.7, 46.4, 46.2, 46.0, 44.83, 44.78, 42.5, 34.51, 34.49, 32.60, 32.55, 31.9, 29.7, 28.7, 28.4, 
28.3, 27.4, 27.33, 27.29, 27.26, 27.09, 27.05, 25.4, 22.7, 22.6, 20.9, 18.1 (6C), 17.9 (6C), 14.1, 
11.9 (3C), 11.8 (3C); HRMS (ESI+) m/z calcd for C79H116Cl4N3O17Si2 [M + H] 1574.6597, found: 
1574.6609. 
 
 
 
1) H2, Lindlar's cat.
    quinoline, EtOAc
O
O O
N
N
O
O
H3C CH3
MTPM
O
Ph
O
NHBoc
RO
RO
R =
OTIPS
OH3C CH3
17
2) OsO4, NMO
    tBuOH, acetone, H2O
O
O O
N
N
O
O
H3C CH3
MTPM
O
O
NHBoc
RO
RO
S5
Ph
HO
HO
 
 
(2R,3R,4R,5S)-2-(((tert-Butoxycarbonyl)amino)methyl)-5-(((1S)-1-((3aR,4R,6R,6aR)-
6-(3-(((2,6-dichloro-4-methoxyphenyl)(2,4-dichlorophenyl)methoxy)methyl)-2,4-
dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-
4-yl)-2,3-dihydroxy-5-phenylpentyl)oxy)tetrahydrofuran-3,4-diyl bis(3,3-dimethyl-5-
((triisopropylsilyl)oxy)pentanoate) (S5). To a stirred solution of 17 (258 mg, 0.16 
mmol) and quinoline (38.7 L, 0.33 mmol) in EtOAc (50 mL) and MeOH (50 mL) was 
added Lindlar catalyst (300 mg). H2 gas was introduced and the reaction mixture was 
stirred under H2 atmosphere (600 psi) at rt. After being stirred for 7 h, the reaction 
mixture was added Lindlar catalyst (150 mg). The reaction mixture was stirred for 11 h 
under H2 atmosphere (600 psi) at rt. The solution was filtered through Celite and washed 
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with 1N HCl (aq.). The combined organic solution was dried over Na2SO4, concentrated 
in vacuo. The crude mixture was used for the next reaction without purification.  To a 
stirred solution of the crude mixture and NMO (192 mg, 1.64 mmol) in t-BuOH/acetone 
(1:1, 2.1 mL) was added OsO4 (4% in water, 1.04 mL, 0.16 mmol) at rt. After being 
stirred for 2 h at 40 
o
C, the reaction mixture was added NMO (192 mg, 1.64 mmol) and 
OsO4 (4% in water, 1.04 mL, 0.16 mmol). After being stirred for 2 h at 40 
o
C, the 
reaction solution was diluted with EtOAc and quenched with saturated NaHCO3 aq./ 
saturated Na2SO3 aq. (2:1). The heterogeneous mixture was stirred for 30 min, extracted 
with EtOAc. The combined organic extracts were dried over Na2SO4 and concentrated in 
vacuo. The crude mixture was passed through a silica gel pad (hexanes/EtOAc 33:67) to 
afford S5 as diastereomeric mixture. This mixture was used for next reaction without 
further purification. 
 
 
 
N
H
O
H3C
NHCbz
HO2C NH2
1) CbzCl, NaHCO3
    THF-H2O
2) 4-Heptylaniline
    Glyceroacetonide-Oxyma
    EDCI, NaHCO3
    DMF-H2O
S6
 
 
Benzyl (4-((4-heptylphenyl)amino)-4-oxobutyl)carbamate (S6). To a stirred solution 
of 4-aminobutyric acid (103 mg, 1 mmol) and NaHCO3 (252 mg, 3 mmol) in THF-H2O 
(1:1, 10 mL) was added CbzCl (214 L, 1.5 mmol). After being stirred for 16 h at rt, the 
reaction mixture was quenched with 1N HCl (aq.) and extracted with CHCl3. The 
combined organic solution was dried over Na2SO4 and concentrated in vacuo. To a stirred 
solution of the crude mixture, 4-heptylaniline (315 L, 1.5 mmol), NaHCO3 (840 mg, 10 
mmol) and Glyceroacetonide-Oxyma (456 mg, 2 mmol) in DMF-H2O (9:1, 5 mL), was 
added EDCI (959 mg, 5 mmol). After being stirred for 9 h at rt, the reaction mixture was 
quenched with H2O and extracted with EtOAc. The combined organic solution was 
washed with 1N HCl (aq.), saturated NaHCO3 (aq.), dried over Na2SO4 and concentrated 
in vacuo. The crude mixture was purified by silica gel column chromatography 
(hexanes/EtOAc 67:33 to 60:40) to afford S6 (284 mg, 0.69 mmol, 69% for 2 steps) 
4
: 
TLC (hexanes/EtOAc 50:50) Rf = 0.40; 
1
H NMR (400 MHz, CDCl3) δ 8.22 (d, J = 19.6 Hz, 1H), 
7.46 (d, J = 8.0 Hz, 2H), 7.36 – 7.30 (m, 5H), 7.11 (d, J = 8.4 Hz, 2H), 5.15 – 5.04 (m, 1H), 5.09 
(s, 2H), 3.30 (q, J = 6.1 Hz, 2H), 2.55 (t, J = 7.6 Hz, 2H), 2.36 (t, J = 7.3 Hz, 2H), 1.90 (q, J = 6.2, 
5.7 Hz, 2H), 1.57 (quin, J = 7.1 Hz, 2H), 1.33 – 1.21 (m, 8H), 0.88 (t, J = 6.6 Hz, 3H); 13C NMR 
(101 MHz, CDCl3) δ 171.1, 157.4, 139.0, 136.3, 135.6, 128.8 (2C), 128.5 (2C), 128.2, 128.1, 
119.9, 66.9, 63.2, 35.4, 34.6, 31.8, 31.5, 29.19, 29.16, 26.7, 22.7, 14.1, 14.0; HRMS (ESI+) m/z 
calcd for C25H34N2NaO3 [M + Na] 433.2467, found: 433.2481. 
 
 
 
N
H
O
H3C
NHCbz
S6
H2, Pd/C
EtOAc-MeOH N
H
O
H3C
NH2
19  
 
4-Amino-N-(4-heptylphenyl)butanamide (19). To a stirred solution of S6 (28.1 mg, 
0.069 mmol) in EtOAc-MeOH (1:1, 10 mL) was added Pd/C (10 wt % 6 mg). H2 gas was 
introduced and the reaction mixture was stirred for 2 h under H2. The solution was 
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filtered through Celite and concentrated in vacuo. The crude mixture of 19 was used for 
next reaction without purification. 
 
1) Pb(OAc)4, NaHCO3
    CH2Cl2
O
O O
N
N
O
O
H3C CH3
MTPMO
O
NHBoc
RO
RO
NC
H
N
R =
OTIPS
OH3C CH3
N
H
O
H3C
21S: 6'S
21R: 6'R
O
O O
N
N
O
O
H3C CH3
MTPM
O
O
NHBoc
RO
RO
Ph
HO
HO
2) 19, 
    (BnO)2P(O)-CH2-P(O)(OBn)OH
    TMSCN, CH2Cl2
S5  
 
(2R,3R,4R,5S)-2-(((tert-Butoxycarbonyl)amino)methyl)-5-((1S,2R)-2-cyano-1-
((3aR,4R,6R,6aR)-6-(3-(((2,6-dichloro-4-methoxyphenyl)(2,4-
dichlorophenyl)methoxy)methyl)-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2,2-
dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-2-((4-((4-heptylphenyl)amino)-4-
oxobutyl)amino)ethoxy)tetrahydrofuran-3,4-diyl bis(3,3-dimethyl-5-
((triisopropylsilyl)oxy)pentanoate) (21S). To a stirred solution of S5 (22.1 mg, 0.014 
mmol) and NaHCO3 (11.5 mg, 0.14 mmol) in CH2Cl2 (0.7 mL) was added Pb(OAc)4 
(12.1 mg, 0.027 mmfol) at 0 
o
C. The reaction mixture was stirred for 2 h at 0 
o
C and 
quenched with saturated NaHCO3 aq., extracted with EtOAc. The combined organic 
extracts were dried over Na2SO4 and concentrated in vacuo. The crude mixture of 
aldehyde 18 was used for the next reaction without purification. To a stirred solution of 
(BnO)2P(O)-CH2-P(O)(OBn)OH (30.6 mg, 0.069 mmol) in CH2Cl2 (0.4 mL) was added a 
CH2Cl2 (0.3 mL) solution of the mixture of 18, 19 was added to the solution. After 9 h, 
the reaction was added TMSCN (17.1 L, 0.14 mmol) and stirred for 9 h at rt. After 
completion, the reaction mixture was quenched with saturated NaHCO3 aq., extracted 
with EtOAc. The combined organic extracts were dried over Na2SO4 and concentrated in 
vacuo. The crude product was purified by silica gel column chromatography 
(hexanes/EtOAc 80:20 to 60:40) to afford 21S (16.7 mg, 9.49 mol, 69% for 2 steps) and 
21R (4.1 mg, 2.34 mol, 17% for 2 steps): TLC (hexanes/EtOAc 60:40) Rf = 0.40; []
21
D 
+0.075 (c = 0.73, CHCl3); IR (thin film) max = 3317 (br), 2930, 2865, 1719, 1675, 1600, 1462, 
1102, 1071, 882, 772, 683 cm
−1
; 
1
H NMR (400 MHz, CDCl3) δ 7.68 (s, 1H), 7.49 (dd, J = 11.4, 
8.8 Hz, 1H), 7.39 (d, J = 7.9 Hz, 2H), 7.32 (s, 1H), 7.19 (d, J = 8.5 Hz, 2H), 7.11 (d, J = 8.0 Hz, 
2H), 6.86 (d, J = 9.3 Hz, 2H), 6.50 (d, J = 15.4 Hz, 1H), 5.73 (dd, J = 23.0, 8.0 Hz, 1H), 5.59 (d, J 
= 5.9 Hz, 1H), 5.54 (d, J = 9.4 Hz, 2H), 5.42 (t, J = 10.1 Hz, 1H), 5.25 (s, 1H), 5.08 – 5.00 (m, 
2H), 4.96 – 4.82 (m, 2H), 4.50 – 4.45 (m, 1H), 4.25 – 4.19 (m, 1H), 4.15 – 4.06 (m, 1H), 3.94 – 
3.83 (m, 1H), 3.80 – 3.63 (m, 10H), 3.49 – 3.41 (m, 1H), 3.39 – 3.31 (m, 1H), 3.03 (dt, J = 12.0, 
6.1 Hz, 1H), 2.71 – 2.61 (m, 1H), 2.54 (t, J = 7.3 Hz, 2H), 2.51 – 2.45 (m, 1H), 2.29 – 2.17 (m, 
4H), 1.67 – 1.51 (m, 10H), 1.41 (s, 9H), 1.28 (dd, J = 15.7, 8.1 Hz, 10H), 1.05 (s, 42H), 1.01 (s, 
6H), 0.95 (s, 6H), 0.87 (t, J = 6.4 Hz, 3H); 
13
C NMR (101 MHz, CDCl3) δ 170.9, 159.5, 136.9, 
136.8, 131.3, 131.2, 129.42, 129.36, 128.84 (2C), 128.82 (2C), 128.80 (2C), 126.4, 126.2, 125.1, 
120.09, 120.05, 115.4, 115.31, 115.30, 114.84, 114.81, 84.90, 84.87, 80.84, 80.78, 80.2, 79.8, 
79.4, 78.2, 76.1, 74.3, 60.0, 59.9, 55.8, 55.7, 52.0, 46.2, 46.0, 44.83, 44.77, 35.4, 32.56, 32.55, 
31.8, 31.5, 29.7, 29.19, 29.16, 28.4, 28.3, 27.3, 27.2, 22.7, 18.1 (12C), 14.1, 11.9 (6C); HRMS 
(ESI+) m/z calcd for C88H135Cl4N6O18Si2 [M + H] 1759.8126, found: 1759.8135. Data for 
(2R,3R,4R,5S)-2-(((tert-butoxycarbonyl)amino)methyl)-5-((1S,2S)-2-cyano-1-
((3aR,4R,6R,6aR)-6-(3-(((2,6-dichloro-4-methoxyphenyl)(2,4-
dichlorophenyl)methoxy)methyl)-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2,2-
dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-2-((4-((4-heptylphenyl)amino)-4-
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oxobutyl)amino)ethoxy)tetrahydrofuran-3,4-diyl bis(3,3-dimethyl-5-
((triisopropylsilyl)oxy)pentanoate) (21R): TLC (hexanes/EtOAc 60:40) Rf = 0.30; 
1
H NMR 
(400 MHz, CDCl3) δ 7.74 (dd, J = 16.8, 11.4 Hz, 1H), 7.51 (dd, J = 11.7, 8.5 Hz, 1H), 7.47 – 7.29 
(m, 3H), 7.23 – 7.15 (m, 2H), 7.10 (t, J = 9.5 Hz, 2H), 6.85 (d, J = 8.8 Hz, 2H), 6.49 (d, J = 4.6 
Hz, 1H), 5.76 (dd, J = 21.1, 8.1 Hz, 1H), 5.65 (d, J = 23.4 Hz, 1H), 5.56 (d, J = 9.2 Hz, 1H), 5.52 
(d, J = 3.9 Hz, 1H), 5.46 (t, J = 10.8 Hz, 1H), 5.40 – 5.23 (m, 2H), 5.23 – 5.16 (m, 1H), 5.10 – 
5.05 (m, 1H), 5.02 (s, 1H), 4.90 – 4.78 (m, 1H), 4.26 (t, J = 6.3 Hz, 1H), 4.21 (d, J = 8.9 Hz, 1H), 
3.96 – 3.89 (m, 1H), 3.80 – 3.71 (m, 10H), 3.68 – 3.63 (m, 1H), 3.48 – 3.39 (m, 1H), 3.04 – 2.95 
(m, 1H), 2.75 – 2.66 (m, 1H), 2.53 (t, J = 7.7 Hz, 2H), 2.44 (d, J = 12.1 Hz, 1H), 2.37 – 2.27 (m, 
2H), 2.23 (d, J = 14.7 Hz, 2H), 1.65 – 1.51 (m, 10H), 1.42 (s, 9H), 1.36 – 1.23 (m, 10H), 1.08 – 
1.01 (m, 42H), 0.97 (s, 6H), 0.90 – 0.85 (m, 9H); HRMS (ESI+) m/z calcd for C88H135Cl4N6O18Si2 
[M + H] 1759.8126, found: 1759.8113. 
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(2S,3R,4R,5R)-2-((1S,2S)-3-Amino-1-((3aR,4R,6R,6aR)-6-(3-(((2,6-dichloro-4-
methoxyphenyl)(2,4-dichlorophenyl)methoxy)methyl)-2,4-dioxo-3,4-
dihydropyrimidin-1(2H)-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-2-
((4-((4-heptylphenyl)amino)-4-oxobutyl)amino)-3-oxopropoxy)-5-(((tert-
butoxycarbonyl)amino)methyl)tetrahydrofuran-3,4-diyl bis(3,3-dimethyl-5-
((triisopropylsilyl)oxy)pentanoate) (22). To a stirred solution of 21S (8.8 mg, 5.0 mol) 
in EtOH/H2O (9:1, 0.5 mL) were added HgCl2 (2.7 mg, 0.010 mmol) and acetaldoxime 
(3.0 L, 0.050 mmol) at rt. After being stirred for 6 h at rt, the reaction mixture was 
concentrated under reduced pressure. The residue was quenched with saturated NaHCO3 
aq., extracted with CHCl3. The combined organic extracts were dried over Na2SO4 and 
concentrated in vacuo. The crude product was purified by silica gel column 
chromatography (CHCl3/MeOH 99.5:0.5 to 99.2:0.8 to 98.8:1.2) to afford 22 (7.9 mg, 4.5 
mol, 89%): TLC (CHCl3/MeOH 95:5) Rf = 0.40; IR (thin film) max = 3335 (br), 2927, 2865, 
1668, 1601, 1460, 1099, 1071, 882, 681 cm
−1
; 
1
H NMR (400 MHz, CDCl3) δ 7.59 (dd, J = 19.5, 
8.5 Hz, 1H), 7.40 (d, J = 8.0 Hz, 2H), 7.30 (t, J = 2.6 Hz, 1H), 7.24 – 7.18 (m, 1H), 7.11 (d, J = 
8.0 Hz, 2H), 6.84 (d, J = 7.2 Hz, 2H), 6.50 (s, 1H), 5.84 (brs, 1H), 5.59 – 5.47 (m, 3H), 5.26 – 
5.14 (m, 2H), 5.06 – 4.97 (m, 1H), 4.96 – 4.87 (m, 1H), 4.84 – 4.73 (m, 1H), 4.55 (t, J = 5.0 Hz, 
1H), 4.28 – 4.14 (m, 2H), 3.80 – 3.70 (m, 7H), 3.59 – 3.46 (m, 1H), 3.41 (brs, 2H), 2.83 (brs, 2H), 
2.54 (t, J = 7.7 Hz, 3H), 2.50 – 2.43 (m, 1H), 2.29 – 2.21 (m, 4H), 1.99 (brs, 2H), 1.65 – 1.53 (m, 
10H), 1.43 (s, 9H), 1.35 (d, J = 5.2 Hz, 3H), 1.32 – 1.24 (m, 10H), 1.05 (d, J = 3.2 Hz, 48H), 1.00 
– 0.97 (m, 6H), 0.87 (t, J = 6.8 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 159.6, 159.5, 136.87, 
136.85, 136.4, 135.2, 134.0, 133.64, 133.59, 131.3, 129.42, 129.40, 128.9 (2C), 126.2, 125.3, 
120.2, 120.1, 115.4 (2C), 74.5, 60.0, 59.9, 55.73, 55.72, 46.2, 46.1, 46.0, 44.8, 35.4, 32.7, 32.6, 
31.8, 31.5, 29.69, 29.67, 29.6, 29.5, 29.4, 29.3, 29.24, 29.16, 29.09, 28.51, 28.49, 28.48, 28.45, 
28.43, 28.42, 28.36, 28.33, 28.31, 28.28, 27.33, 27.30, 27.25, 27.2, 25.3, 22.7, 18.1 (12C), 14.1, 
11.9 (6C); HRMS (ESI+) m/z calcd for C88H137Cl4N6O19Si2 [M + H] 1777.8231, found: 
1777.8219. 
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4-(((2S,3S)-1-Amino-3-(((2S,3R,4S,5R)-5-(aminomethyl)-3,4-
dihydroxytetrahydrofuran-2-yl)oxy)-3-((2S,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-
1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)-1-oxopropan-2-yl)amino)-N-(4-
heptylphenyl)butanamide (10). To a stirred solution of 22 (7.9 mg, 4.5 mol) in CH2Cl2 
(0.70 mL) was added TFA (0.30 mL). The reaction mixture was stirred for 1 h at rt, and 
all volatile were evaporated in vacuo. To a stirred solution of the crude mixture in H2O 
(0.2 mL) was added TFA (0.8 mL). The reaction mixture was stirred for 2 h at 40 
o
C, and 
all volatile were evaporated in vacuo. The crude mixture was purified by silica gel 
column chromatography (CHCl3/MeOH 80:20 to CHCl3/MeOH/H2O/50% aqueous 
ammonia 56:42:7:3) to afford 10 (UT-17455) (2.4 mg, 3.4 mol, 76%, 95.8% purity): 
TLC (n-butanol/ethanol/CHCl3/28% aqueous ammonia 4:7:2:7) Rf = 0.50; []
21
D +0.538 (c = 0.24, 
methanol); IR (thin film) max = 3302 (br), 2926, 1672, 1542, 1412, 1271, 1131, 1111, 1062, 819, 
721 cm
−1
;
 1
H NMR (400 MHz, CD3OD) δ 7.77 (d, J = 8.1 Hz, 1H), 7.43 (d, J = 8.1 Hz, 2H), 7.12 
(d, J = 8.0 Hz, 2H), 5.74 (s, 1H), 5.73 (d, J = 12.6 Hz, 1H), 5.14 (s, 1H), 4.21 (dd, J = 4.7, 4.2 Hz, 
1H), 4.19 – 4.13 (m, 2H), 4.11 (t, J = 4.7 Hz, 1H), 4.08 (s, 2H), 4.02 – 3.99 (m, 1H), 3.50 (d, J = 
8.9 Hz, 1H), 3.24 (d, J = 13.0 Hz, 1H), 3.16 – 3.09 (m, 1H), 2.73 – 2.60 (m, 2H), 2.57 (t, J = 7.7 
Hz, 2H), 2.43 (dd, J = 7.4, 4.0 Hz, 2H), 1.86 (quin, J = 7.2 Hz, 2H), 1.59 (quin, J = 6.4, 5.7 Hz, 
2H), 1.35 – 1.26 (m, 8H), 0.92 – 0.87 (m, 3H); 13C NMR (101 MHz, CD3OD) δ 177.2, 174.2, 
166.1, 152.1, 142.6, 140.1, 137.4, 129.7 (2C), 121.5 (2C), 110.6, 102.7, 92.5, 85.2, 80.5, 76.4, 
75.0, 73.0, 71.2, 64.3, 43.2, 36.3, 35.5, 33.0, 32.8, 30.3, 26.6, 23.7, 14.4; HRMS (ESI+) m/z calcd 
for C33H51N6O11 [M + H] 707.3616, found: 707.3624. 
 
Figure S2. HPLC analysis of 10 (UT-17455). 
 
Area % purity: 95.8% 
Conditions: 
column: Phenomenex Kinetex 1.7  XB-C18 100 Å 150 x 2.10 mm column, solvents: 80 : 20 
MeOH : 0.05M NH4HCO3 in water, UV: 254 nm 
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(2S,3R,4R,5R)-2-((1S,2S)-3-Amino-1-((3aR,4R,6R,6aR)-6-(3-(((2,6-dichloro-4-
methoxyphenyl)(2,4-dichlorophenyl)methoxy)methyl)-2,4-dioxo-3,4-
dihydropyrimidin-1(2H)-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-2-
((4-((4-heptylphenyl)amino)-4-oxobutyl)(methyl)amino)-3-oxopropoxy)-5-(((tert-
butoxycarbonyl)amino)methyl)tetrahydrofuran-3,4-diyl bis(3,3-dimethyl-5-
((triisopropylsilyl)oxy)pentanoate) (23). To a stirred solution of 22 (5.8 mg, 3.3 mol) 
and paraformaldehyde (2.9 mg, 0.098 mmol) in CH3CN (0.5 mL) were added 
NaB(CN)H3 (6.2 mg, 0.098 mmol). After being stirred for 4 h at rt, the reaction mixture 
was quenched with saturated NaHCO3 aq., extracted with CHCl3. The combined organic 
extracts were dried over Na2SO4 and concentrated in vacuo. The crude product was 
purified by silica gel column chromatography (hexanes/EtOAc 40:60) to afford 23 (5.5 
mg, 3.1 mol, 95%): TLC (hexanes/EtOAc 33:67) Rf = 0.60; []
21
D +0.022 (c = 0.28, CHCl3); 
IR (thin film) max = 2932, 2866, 1718, 1672, 1601, 1463, 1101, 1071, 884 cm
−1
; 
1
H NMR (400 
MHz, CDCl3) δ 7.75 (d, J = 17.0 Hz, 1H), 7.56 (d, J = 8.6 Hz, 1H), 7.43 (d, J = 8.1 Hz, 2H), 7.34 
(d, J = 8.1 Hz, 1H), 7.30 (s, 2H), 7.20 (dt, J = 8.5, 2.0 Hz, 1H), 7.10 (d, J = 8.1 Hz, 2H), 6.85 (s, 
2H), 6.51 (d, J = 7.9 Hz, 1H), 6.28 (brs, 1H), 5.95 (d, J = 21.6 Hz, 1H), 5.84 – 5.78 (m, 1H), 5.74 
(d, J = 23.3 Hz, 1H), 5.54 (s, 2H), 5.49 (d, J = 9.6 Hz, 1H), 5.18 (brs, 1H), 5.11 (s, 2H), 5.02 (brs, 
1H), 4.88 – 4.83 (m, 1H), 4.80 – 4.74 (m, 1H), 4.39 – 4.31 (m, 2H), 4.24 – 4.18 (m, 1H), 3.92 (t, 
J = 5.8 Hz, 1H), 3.78 (s, 3H), 3.74 (q, J = 6.6 Hz, 4H), 3.68 – 3.63 (m, 1H), 3.50 – 3.40 (m, 2H), 
3.37 – 3.30 (m, 1H), 2.83 – 2.74 (m, 1H), 2.68 – 2.59 (m, 1H), 2.54 (t, J = 7.8 Hz, 2H), 2.49 (s, 
3H), 2.37 (q, J = 8.0, 7.6 Hz, 2H), 2.29 – 2.20 (m, 4H), 1.98 – 1.88 (m, 2H), 1.62 – 1.52 (m, 6H), 
1.40 (s, 9H), 1.36 (brs, 3H), 1.33 – 1.23 (m, 6H), 1.09 – 1.01 (m, 48H), 0.98 (s, 6H), 0.87 (t, J = 
6.4 Hz, 3H); 
13
C NMR (101 MHz, CDCl3) δ 171.0, 162.0, 159.5, 157.1, 136.9, 131.3, 129.4, 
128.7 (2C), 119.9 (2C), 115.3, 115.1, 114.2, 70.6, 70.1, 69.9, 67.1, 60.4, 60.1, 59.96, 59.95, 58.9, 
55.8, 55.7, 54.4, 54.1, 46.22, 46.16, 46.1, 45.3, 44.9, 44.8, 44.7, 42.3, 41.2, 39.93, 39.86, 39.6, 
39.04, 38.97, 35.4, 32.7, 32.64, 32.63, 32.62, 32.58, 31.9, 31.8, 31.7, 31.6, 31.53, 31.48, 29.69, 
29.67, 29.6, 29.4, 29.22, 29.17, 28.50, 28.49, 28.4, 27.29, 27.28, 27.21, 27.17, 25.23, 25.20, 22.68, 
22.66, 18.1 (12C), 14.1, 11.9 (6C); HRMS (ESI+) m/z calcd for C89H139Cl4N6O19Si2 [M + H] 
1791.8388, found: 1791.8404. 
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4-(((2S,3S)-1-Amino-3-(((2S,3R,4S,5R)-5-(aminomethyl)-3,4-
dihydroxytetrahydrofuran-2-yl)oxy)-3-((2S,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-
1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)-1-oxopropan-2-yl)(methyl)amino)-N-
(4-heptylphenyl)butanamide (9). To a stirred solution of 23 (2.9 mg, 1.6 mol) in 
CH2Cl2 (0.70 mL) was added TFA (0.30 mL). The reaction mixture was stirred for 2 h at 
rt, and all volatile were evaporated in vacuo. To a stirred solution of the crude mixture in 
H2O (0.2 mL) was added TFA (0.8 mL). The reaction mixture was stirred for 4 h at 40 
o
C, 
and all volatile were evaporated in vacuo. The crude mixture was purified by silica gel 
column chromatography (CHCl3/MeOH 80:20 to CHCl3/MeOH/H2O/50% aqueous 
ammonia 56:42:7:3) to afford 9 (UT-17415) (1.2 mg, 1.6 mol, 100%): TLC (n-
butanol/ethanol/CHCl3/28% aqueous ammonia 4:7:2:7) Rf = 0.55; []
20
D +0.038 (c = 0.12, 
methanol); IR (thin film) max = 3333 (br), 2926, 2855, 1676, 1204, 1135, 840, 801, 722 cm
−1
; 
1
H 
NMR (400 MHz, CD3OD) δ 7.82 (d, J = 8.1 Hz, 1H), 7.44 (d, J = 8.0 Hz, 2H), 7.12 (d, J = 8.1 Hz, 
2H), 5.76 (d, J = 8.0 Hz, 1H), 5.70 (s, 1H), 5.18 (s, 1H), 4.58 (s, 1H), 4.28 (d, J = 9.3 Hz, 1H), 
4.21 – 4.16 (m, 3H), 4.14 – 4.07 (m, 3H), 3.61 (d, J = 9.4 Hz, 1H), 3.21 (dd, J = 13.6, 3.4 Hz, 1H), 
2.83 (td, J = 12.1, 11.7, 5.0 Hz, 1H), 2.57 (t, J = 7.6 Hz, 2H), 2.46 (s, 3H), 2.46 – 2.40 (m, 2H), 
2.00 – 1.89 (m, 1H), 1.79 (d, J = 12.4 Hz, 1H), 1.63 – 1.55 (m, 2H), 1.37 – 1.23 (m, 10H), 0.91 – 
0.87 (m, 3H); 
13
C NMR (101 MHz, CD3OD) δ 173.9, 172.3, 142.4, 140.2, 137.3, 129.7 (2C), 
121.5 (2C), 112.1, 102.4, 92.5, 84.2, 80.5, 78.4, 76.4, 75.4, 72.0, 70.8, 68.5, 54.5, 39.5, 36.3, 35.0, 
33.0, 32.8, 30.29, 30.26, 24.3, 23.7, 14.4; HRMS (ESI+) m/z calcd for C34H53N6O11 [M + H] 
721.3772, found: 721.3761. 
 
Figure S3. HPLC analysis of 9 (UT-17415). 
 
Area % purity: 97.2% 
Conditions: 
column: Phenomenex Kinetex 1.7  XB-C18 100 Å 150 x 2.10 mm column, solvents: 80 : 20 
MeOH : 0.05M NH4HCO3 in water, UV: 254 nm 
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(4-(4-(4-(Trifluoromethoxy)phenoxy)piperidin-1-yl)phenyl)methanamine (S7). The 
title compound was synthesized according to the reported procedure 
5
: 1H NMR (400 MHz, 
CDCl3) δ 7.21 (d, J = 8.2 Hz, 2H), 7.14 (d, J = 8.6 Hz, 2H), 6.97 – 6.87 (m, 4H), 4.43 (tt, J = 7.7, 
3.8 Hz, 1H), 3.79 (s, 2H), 3.49 (ddd, J = 11.7, 7.2, 3.7 Hz, 2H), 3.09 (ddd, J = 12.2, 8.2, 3.6 Hz, 
2H), 2.15 – 2.06 (m, 2H), 1.98 – 1.88 (m, 2H); 13C NMR (101 MHz, CDCl3) δ 155.8, 150.2, 
142.8, 134.6, 128.0 (2C), 122.5 (2C), 116.83 (2C), 116.76 (2C), 72.9, 46.9 (2C), 45.9, 30.4 (2C); 
HRMS (ESI+) m/z calcd for C19H22F3N2O2 [M + H] 367.1633, found 367.1628. 
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Benzyl (4-oxo-4-((4-(4-(4-(trifluoromethoxy)phenoxy)piperidin-1-
yl)benzyl)amino)butyl)carbamate (S8). To a stirred solution of 4-aminobutyric acid 
(61.9 mg, 0.60 mmol) and NaHCO3 (151 mg, 1.80 mmol) in THF-H2O (1:1, 6 mL) was 
added CbzCl (128 L, 0.90 mmol). After being stirred for 8 h at rt, the reaction mixture 
was quenched with 1N HCl (aq.) and extracted with CHCl3. The combined organic 
solution was dried over Na2SO4 and concentrated in vacuo. To a stirred solution of the 
crude mixture, S7 (110 mg, 0.30 mmol), NaHCO3 (126 mg, 1.50 mmol) and 
Glyceroacetonide-Oxyma (103 mg, 0.45 mmol) in DMF-H2O (9:1, 1.5 mL), was added 
EDCI (115 mg, 2.0 mmol). After being stirred for 13 h at rt, the reaction mixture was 
quenched with H2O and extracted with EtOAc. The combined organic solution was 
washed with 1N HCl (aq.), saturated NaHCO3 (aq.), dried over Na2SO4 and concentrated 
in vacuo. The crude mixture was purified by silica gel column chromatography 
(hexanes/EtOAc 33:67 to 20:80) to afford S8 (102 mg, 0.17 mmol, 58%) 
4
: TLC 
(hexanes/EtOAc 20:80) Rf = 0.30; 
1
H NMR (400 MHz, CDCl3) δ 7.37 – 7.33 (m, 5H), 7.16 (dd, J 
= 14.6, 8.4 Hz, 4H), 6.91 (d, J = 9.1 Hz, 4H), 5.96 (brs, 1H), 5.09 (s, 2H), 5.04 (brs, 1H), 4.44 (tt, 
J = 7.4, 3.7 Hz, 1H), 4.34 (d, J = 5.5 Hz, 2H), 3.48 (ddd, J = 11.7, 7.3, 3.7 Hz, 2H), 3.25 (q, J = 
6.4 Hz, 2H), 3.10 (ddd, J = 12.2, 8.2, 3.5 Hz, 2H), 2.23 (t, J = 7.0 Hz, 2H), 2.14 – 2.05 (m, 2H), 
1.94 (tt, J = 8.6, 3.9 Hz, 2H), 1.86 (p, J = 6.6 Hz, 2H); 
13
C NMR (101 MHz, CDCl3) δ 172.1, 
155.8, 136.5, 128.9 (2C), 128.5 (2C), 128.11, 128.08, 122.5 (2C), 116.8 (2C), 116.6 (2C), 72.8, 
66.7, 46.6 (2C), 43.2, 40.4, 33.7, 30.3 (2C), 26.0; HRMS (ESI+) m/z calcd for C31H35F3N3O5 [M 
+ Na] 586.2529, found: 586.2521. 
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4-Amino-N-(4-(4-(4-(trifluoromethoxy)phenoxy)piperidin-1-yl)benzyl)butanamide 
(20). To a stirred solution of S8 (59 mg, 0.10 mmol) in EtOAc-MeOH (1:1, 10 mL) was 
added Pd/C (10 wt % 12 mg). H2 gas was introduced and the reaction mixture was stirred 
for 3 h under H2. The solution was filtered through Celite and concentrated in vacuo. The 
crude mixture of 20 was used for next reaction without purification. 
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(2R,3R,4R,5S)-2-(((tert-Butoxycarbonyl)amino)methyl)-5-((1S,2R)-2-cyano-1-
((3aR,4R,6R,6aR)-6-(3-(((2,6-dichloro-4-methoxyphenyl)(2,4-
dichlorophenyl)methoxy)methyl)-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2,2-
dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-2-((4-oxo-4-((4-(4-(4-
(trifluoromethoxy)phenoxy)piperidin-1-
yl)benzyl)amino)butyl)amino)ethoxy)tetrahydrofuran-3,4-diyl bis(3,3-dimethyl-5-
((triisopropylsilyl)oxy)pentanoate) (24S). To a stirred solution of S5 (32.5 mg, 0.020 
mmol) and NaHCO3 (16.9 mg, 0.20 mmol) in CH2Cl2 (1.0 mL) was added Pb(OAc)4 
(17.9 mg, 0.040 mmfol) at 0 
o
C. The reaction mixture was stirred for 2 h at 0 
o
C and 
quenched with saturated NaHCO3 aq., extracted with EtOAc. The combined organic 
extracts were dried over Na2SO4 and concentrated in vacuo. The crude mixture of 
aldehyde 18 was used for the next reaction without purification. To a stirred solution of 
(BnO)2P(O)-CH2-P(O)(OBn)OH (45.0 mg, 0.10 mmol) in CH2Cl2 (0.5 mL) was added a 
CH2Cl2 (0.5 mL) solution of the mixture of 18, 20 was added to the solution. After 6 h, 
the reaction was added TMSCN (25.2 L, 0.20 mmol) and stirred for 12 h at rt. After 
completion, the reaction mixture was quenched with saturated NaHCO3 aq., extracted 
with EtOAc. The combined organic extracts were dried over Na2SO4 and concentrated in 
vacuo. The crude product was purified by silica gel column chromatography 
(hexanes/EtOAc 80:20 to 60:40) to afford 24S (23.9 mg, 0.012 mmol, 61% for 2 steps) 
and 24R (5.1 mg, 2.56 mol, 13% for 2 steps): TLC (hexanes/EtOAc 50:50) Rf = 0.40; []
21
D 
+0.102 (c = 0.75, CHCl3); IR (thin film) max = 3342 (br), 2941, 2866, 1718, 1675, 1505, 1464, 
1243, 1164, 1101, 1071, 883, 772, 688 cm
−1
; 
1
H NMR (400 MHz, CDCl3) δ 7.49 (dd, J = 8.5, 4.3 
Hz, 1H), 7.32 (d, J = 2.0 Hz, 1H), 7.22 – 7.11 (m, 7H), 6.94 – 6.88 (m, 5H), 6.86 (d, J = 6.5 Hz, 
2H), 6.50 (d, J = 8.6 Hz, 1H), 6.25 – 6.16 (m, 1H), 5.73 (dd, J = 22.2, 8.0 Hz, 1H), 5.60 (t, J = 8.8 
Hz, 1H), 5.56 – 5.41 (m, 3H), 5.21 (d, J = 4.4 Hz, 1H), 5.05 – 4.98 (m, 2H), 4.94 – 4.77 (m, 2H), 
4.53 – 4.37 (m, 3H), 4.25 – 4.16 (m, 2H), 4.05 – 3.98 (m, 1H), 3.80 – 3.69 (m, 6H), 3.68 – 3.63 
(m, 1H), 3.56 (dd, J = 17.3, 3.4 Hz, 1H), 3.48 (ddt, J = 11.6, 7.2, 4.0 Hz, 2H), 3.44 – 3.29 (m, 1H), 
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3.08 (dq, J = 9.5, 5.3, 4.8 Hz, 2H), 2.95 (dt, J = 11.4, 5.5 Hz, 1H), 2.47 (td, J = 12.0, 11.4, 5.7 Hz, 
1H), 2.36 – 2.14 (m, 5H), 2.13 – 2.05 (m, 2H), 1.97 – 1.85 (m, 3H), 1.84 – 1.75 (m, 1H), 1.58 (t, 
J = 6.9 Hz, 2H), 1.55 – 1.50 (m, 4H), 1.40 (s, 9H), 1.33 (d, J = 4.8 Hz, 3H), 1.28 – 1.23 (m, 3H), 
1.08 – 1.02 (m, 42H), 1.01 (s, 6H), 0.94 (d, J = 2.1 Hz, 6H); 13C NMR (101 MHz, CDCl3) δ 172.4, 
171.0, 170.9, 159.5, 155.8, 150.9, 150.7, 142.8, 136.9, 136.8, 135.3, 135.1, 134.13, 134.05, 
133.86, 133.85, 133.78, 131.2, 131.1, 129.42, 129.37, 129.0, 126.4, 126.2, 125.5, 125.2, 122.5 
(2C), 121.8, 119.3, 118.4, 116.8 (2C), 116.6 (2C), 115.4, 115.3, 114.71, 114.66, 106.4, 102.3, 
102.2, 84.8, 80.7, 80.6, 79.9, 79.8, 79.3, 76.2, 74.32, 74.30, 72.9, 60.38, 60.35, 60.0, 59.9, 55.72, 
55.71, 52.0, 46.6, 46.2, 45.9, 44.84, 44.77, 42.99, 42.96, 42.4, 41.2, 33.53, 33.49, 32.6, 32.5, 30.3, 
28.4, 27.3 (2C), 27.17, 27.16, 27.1, 25.4, 18.1 (12C), 14.2, 14.1, 11.91 (3C), 11.90 (3C); HRMS 
(ESI+) m/z calcd for C94H135Cl4F3N7O20Si2 [M + H] 1934.8007, found: 1934.8021. Data for 24R: 
TLC (hexanes/EtOAc 60:40) Rf = 0.30; 
1
H NMR (400 MHz, Chloroform-d) δ 7.53 (d, J = 8.7 Hz, 
1H), 7.33 – 7.29 (m, 1H), 7.21 – 7.07 (m, 7H), 6.94 – 6.88 (m, 5H), 6.85 (d, J = 6.8 Hz, 2H), 6.54 
(s, 1H), 5.71 (d, J = 7.9 Hz, 1H), 5.58 – 5.49 (m, 3H), 5.46 (t, J = 8.9 Hz, 1H), 5.24 – 5.20 (m, 
1H), 5.15 – 5.08 (m, 1H), 5.08 – 5.00 (m, 1H), 4.92 (dd, J = 11.5, 5.6 Hz, 1H), 4.85 – 4.78 (m, 
1H), 4.49 – 4.39 (m, 2H), 4.39 – 4.18 (m, 3H), 3.98 (dd, J = 11.1, 5.4 Hz, 1H), 3.81 – 3.70 (m, 
6H), 3.69 – 3.61 (m, 2H), 3.52 – 3.43 (m, 2H), 3.37 – 3.32 (m, 1H), 3.08 (ddd, J = 12.4, 8.5, 3.8 
Hz, 2H), 2.99 – 2.91 (m, 1H), 2.65 (dd, J = 12.8, 6.5 Hz, 1H), 2.31 – 2.18 (m, 5H), 2.13 – 2.04 (m, 
2H), 1.96 – 1.85 (m, 4H), 1.67 – 1.52 (m, 6H), 1.40 (s, 9H), 1.38 – 1.29 (m, 3H), 1.25 (s, 6H), 
1.10 – 0.98 (m, 42H), 0.97 (s, 6H), 0.88 (t, J = 6.7 Hz, 3H) ; HRMS (ESI+) m/z calcd for 
C94H135Cl4F3N7O20Si2 [M + H] 1934.8007, found: 1934.8000. 
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(2S,3R,4R,5R)-2-((1S,2S)-3-Amino-1-((3aR,4R,6R,6aR)-6-(3-(((2,6-dichloro-4-
methoxyphenyl)(2,4-dichlorophenyl)methoxy)methyl)-2,4-dioxo-3,4-
dihydropyrimidin-1(2H)-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-3-
oxo-2-((4-oxo-4-((4-(4-(4-(trifluoromethoxy)phenoxy)piperidin-1-
yl)benzyl)amino)butyl)amino)propoxy)-5-(((tert-
butoxycarbonyl)amino)methyl)tetrahydrofuran-3,4-diyl bis(3,3-dimethyl-5-
((triisopropylsilyl)oxy)pentanoate) (25). To a stirred solution of 24S (15.4 mg, 8.0 
mol) in EtOH/H2O (9:1, 0.5 mL) were added HgCl2 (4.3 mg, 0.016 mmol) and 
acetaldoxime (4.9 L, 0.080 mmol) at rt. After being stirred for 6 h at rt, the reaction 
mixture was concentrated under reduced pressure. The residue was quenched with 
saturated NaHCO3 aq., extracted with CHCl3. The combined organic extracts were dried 
over Na2SO4 and concentrated in vacuo. The crude product was purified by silica gel 
column chromatography (CHCl3/MeOH 99.5:0.5 to 99.2:0.8 to 98.8:1.2) to afford 25 
(15.3 mg, 7.8 mol, 98%): TLC (CHCl3/MeOH 95:5) Rf = 0.30; []
21
D +0.144 (c = 0.53, 
CHCl3); IR (thin film) max = 3335 (br), 2940, 2866, 1719, 1676, 1505, 1464, 1367, 1242, 1162, 
1101, 1070, 882, 681 cm
−1
; 
1
H NMR (400 MHz, CDCl3) δ 7.53 (dd, J = 8.6, 5.1 Hz, 1H), 7.30 (s, 
1H), 7.28 – 7.22 (m, 2H), 7.21 – 7.12 (m, 6H), 6.91 (d, J = 8.5 Hz, 4H), 6.86 (d, J = 2.6 Hz, 2H), 
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6.51 (d, J = 8.7 Hz, 1H), 5.94 (brs, 1H), 5.79 – 5.67 (m, 3H), 5.56 – 5.47 (m, 2H), 5.17 (brs, 1H), 
5.06 (s, 1H), 4.96 (brs, 1H), 4.82 – 4.73 (m, 2H), 4.43 (tt, J = 7.8, 3.8 Hz, 1H), 4.39 – 4.28 (m, 
3H), 4.21 (brs, 1H), 4.13 (brs, 1H), 3.78 (s, 3H), 3.73 (q, J = 7.4 Hz, 5H), 3.67 (brs, 1H), 3.48 
(ddd, J = 11.7, 7.2, 3.7 Hz, 2H), 3.41 – 3.28 (m, 1H), 3.17 (s, 1H), 3.09 (ddd, J = 12.2, 8.2, 3.3 Hz, 
2H), 2.80 – 2.60 (m, 2H), 2.38 – 2.15 (m, 7H), 2.13 – 2.05 (m, 2H), 1.93 (ddd, J = 12.8, 8.0, 3.7 
Hz, 2H), 1.85 – 1.79 (m, 2H), 1.54 (s, 3H), 1.42 (s, 9H), 1.34 (s, 3H), 1.04 (d, J = 2.8 Hz, 42H), 
1.01 (s, 6H), 0.96 (s, 6H); 
13
C NMR (101 MHz, CDCl3) δ 162.1, 162.0, 159.6, 159.5, 156.2, 155.8, 
150.9, 150.4, 142.80, 142.78, 136.88, 136.86, 135.23, 135.21, 133.9, 133.6, 131.33, 131.30, 
131.29, 129.40, 129.37, 129.2, 129.1, 129.02, 128.98, 126.24, 126.22, 126.21, 125.40, 125.36, 
124.5, 124.4, 123.20, 123.19, 122.5 (2C), 121.8, 120.1, 119.3, 116.8 (2C), 115.4, 80.4, 80.02, 
79.99, 79.96, 79.95, 79.92, 79.87, 79.85, 79.83, 74.51, 74.50, 72.7, 70.4, 70.3, 69.5, 60.0, 59.9, 
55.73, 55.72, 46.7, 46.19, 46.15, 46.13, 46.11, 46.10, 46.07, 46.0, 44.8, 34.7, 34.5, 32.61, 32.58, 
30.2, 29.7, 29.64, 29.60, 28.50, 28.45, 28.42, 28.38, 28.34, 27.25 (2C), 27.19, 27.16, 25.31, 25.29, 
25.27, 18.1 (12C), 14.1, 12.2, 11.9 (6C); HRMS (ESI+) m/z calcd for C94H137Cl4F3N7O21Si2 [M + 
H] 1952.8112, found: 1952.8098. 
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4-(((2S,3S)-1-Amino-3-(((2S,3R,4S,5R)-5-(aminomethyl)-3,4-
dihydroxytetrahydrofuran-2-yl)oxy)-3-((2S,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-
1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)-1-oxopropan-2-yl)amino)-N-(4-(4-(4-
(trifluoromethoxy)phenoxy)piperidin-1-yl)benzyl)butanamide (11). To a stirred 
solution of 25 (5.3 mg, 2.7 mol) in CH2Cl2 (0.70 mL) was added TFA (0.30 mL). The 
reaction mixture was stirred for 1 h at rt, and all volatile were evaporated in vacuo. To a 
stirred solution of the crude mixture in H2O (0.2 mL) was added TFA (0.8 mL). The 
reaction mixture was stirred for 2 h at 40 
o
C, and all volatile were evaporated in vacuo. 
The crude mixture was purified by silica gel column chromatography (CHCl3/MeOH 
80:20 to CHCl3/MeOH/H2O/50% aqueous ammonia 56:42:7:3) to afford 11 (UT-17460) 
(2.2 mg, 2.5 mol, 91%): TLC (n-butanol/ethanol/CHCl3/28% aqueous ammonia 4:7:2:7) Rf = 
0.50; []21D +0.375 (c = 0.30, methanol); IR (thin film) max = 3352 (br), 2932, 1677, 1505, 1243, 
1201, 1136, 801, 722 cm
−1
; 
1
H NMR (400 MHz, CD3OD) δ 7.78 (d, J = 8.1 Hz, 1H), 7.18 (dd, J = 
9.0, 3.5 Hz, 4H), 7.00 (dd, J = 16.0, 8.6 Hz, 4H), 5.77 (d, J = 2.9 Hz, 1H), 5.73 (d, J = 8.1 Hz, 
1H), 5.14 (s, 1H), 4.57 – 4.50 (m, 1H), 4.28 (s, 2H), 4.22 – 4.13 (m, 3H), 4.10 (dd, J = 8.6, 4.4 Hz, 
1H), 4.07 – 3.98 (m, 2H), 3.52 – 3.46 (m, 3H), 3.44 (d, J = 8.8 Hz, 1H), 3.17 (d, J = 13.0 Hz, 1H), 
3.14 – 3.02 (m, 3H), 2.60 (ddq, J = 18.4, 11.8, 6.9 Hz, 2H), 2.29 (td, J = 7.3, 2.8 Hz, 2H), 2.12 
(dd, J = 14.5, 5.6 Hz, 2H), 1.93 – 1.73 (m, 4H), 1.39 – 1.25 (m, 2H); 13C NMR (101 MHz, 
CD3OD) δ 175.6, 166.2, 157.6, 152.0, 142.6, 131.2, 129.6 (2C), 123.6 (2C), 118.11 (2C), 118.07 
(2C), 110.5, 102.7, 92.3, 85.3, 81.4, 80.4, 76.5, 75.1, 74.1 (2C), 73.0, 71.3, 64.4, 43.7, 43.6, 34.7, 
31.5, 26.9; HRMS (ESI+) m/z calcd for C39H51F3N7O13 [M + H] 882.3497, found: 882.3512. 
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Figure S4. HPLC analysis of 11 (UT-17460). 
 
Area % purity: 95.6% 
Conditions: 
column: Phenomenex Kinetex 1.7  XB-C18 100 Å 150 x 2.10 mm column, solvents: 75 : 25 
MeOH : 0.05M NH4HCO3 in water, UV: 254 nm 
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(2S,3R,4R,5R)-2-((1S,2S)-3-Amino-1-((3aR,4R,6R,6aR)-6-(3-(((2,6-dichloro-4-
methoxyphenyl)(2,4-dichlorophenyl)methoxy)methyl)-2,4-dioxo-3,4-
dihydropyrimidin-1(2H)-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-2-
(methyl(4-oxo-4-((4-(4-(4-(trifluoromethoxy)phenoxy)piperidin-1-
yl)benzyl)amino)butyl)amino)-3-oxopropoxy)-5-(((tert-
butoxycarbonyl)amino)methyl)tetrahydrofuran-3,4-diyl bis(3,3-dimethyl-5-
((triisopropylsilyl)oxy)pentanoate) (26). To a stirred solution of 25 (7.8 mg, 4.0 mol) 
and paraformaldehyde (3.6 mg, 0.12 mmol) in CH3CN (0.5 mL) were added NaB(CN)H3 
(7.5 mg, 0.12 mmol). After being stirred for 17 h at rt, the reaction mixture was quenched 
with saturated NaHCO3 aq., extracted with CHCl3. The combined organic extracts were 
dried over Na2SO4 and concentrated in vacuo. The crude product was purified by silica 
gel column chromatography (hexanes/EtOAc 33:67) to afford 26 (4.7 mg, 2.4 mol, 
59%): TLC (hexanes/EtOAc 20:80) Rf = 0.50; 
1
H NMR (400 MHz, Chloroform-d) δ 7.57 (d, J = 
8.8 Hz, 1H), 7.38 (dd, J = 19.7, 7.9 Hz, 1H), 7.29 (s, 1H), 7.22 – 7.10 (m, 5H), 6.90 (d, J = 9.1 Hz, 
4H), 6.85 (d, J = 3.6 Hz, 2H), 6.51 (d, J = 5.1 Hz, 1H), 6.25 (d, J = 27.7 Hz, 1H), 5.84 (dd, J = 
13.4, 8.0 Hz, 1H), 5.55 (s, 1H), 5.48 (brs, 1H), 5.13 (brs, 1H), 5.09 (s, 1H), 4.99 (brs, 1H), 4.86 (d, 
J = 6.3 Hz, 1H), 4.74 (d, J = 7.0 Hz, 1H), 4.43 (tt, J = 7.5, 3.6 Hz, 1H), 4.36 – 4.28 (m, 4H), 4.20 
(dd, J = 8.6, 3.5 Hz, 1H), 3.77 (s, 3H), 3.74 (t, J = 6.5 Hz, 4H), 3.69 – 3.63 (m, 2H), 3.51 – 3.42 
(m, 4H), 3.29 (d, J = 14.5 Hz, 1H), 3.08 (ddd, J = 12.2, 8.4, 3.4 Hz, 2H), 2.76 – 2.68 (m, 1H), 
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2.61 – 2.51 (m, 1H), 2.45 (s, 3H), 2.29 – 2.14 (m, 5H), 2.12 – 2.05 (m, 2H), 1.96 – 1.83 (m, 4H), 
1.55 (s, 3H), 1.39 (s, 9H), 1.37 (s, 3H), 1.26 (s, 3H), 1.04 (d, J = 4.6 Hz, 42H), 1.01 (s, 6H), 0.99 
(s, 6H); 
13
C NMR (101 MHz, CDCl3) δ 173.0, 172.3, 171.22, 171.15, 162.0, 159.5, 157.5, 155.8, 
150.6, 142.83, 142.81, 136.9, 135.4, 131.3, 129.36, 129.35, 129.31, 129.30, 129.03, 128.99, 
128.95, 128.93, 126.1, 122.5 (2C), 116.8 (2C), 116.6, 115.33, 115.29, 107.3, 106.9, 84.1, 79.30, 
79.28, 79.26, 79.24, 79.23, 74.88, 74.87, 73.6, 72.83, 72.80, 70.61, 70.56, 69.8, 67.3, 60.39, 60.36, 
60.0, 59.9, 55.70 (2C), 54.2, 46.6 (2C), 46.1, 46.0, 45.0, 44.9, 44.7, 43.1, 41.2, 32.61, 32.59, 
30.33 (2C), 30.27, 30.25, 29.69, 29.67, 29.65, 29.60, 28.52, 28.45, 27.31, 27.28, 27.24, 27.23, 
27.22, 27.15, 25.14, 25.11, 22.7, 18.1 (12C), 14.2, 14.1, 11.9 (6C); HRMS (ESI+) m/z calcd for 
C95H139Cl4F3N7O21Si2 [M + H] 1966.8269, found: 1966.8288. 
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4-(((2S,3S)-1-Amino-3-(((2S,3R,4S,5R)-5-(aminomethyl)-3,4-
dihydroxytetrahydrofuran-2-yl)oxy)-3-((2S,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-
1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)-1-oxopropan-2-yl)(methyl)amino)-N-
(4-(4-(4-(trifluoromethoxy)phenoxy)piperidin-1-yl)benzyl)butanamide (12). To a 
stirred solution of 26 (4.7 mg, 2.4 mol) in CH2Cl2 (0.70 mL) was added TFA (0.30 mL). 
The reaction mixture was stirred for 2 h at rt, and all volatile were evaporated in vacuo. 
To a stirred solution of the crude mixture in H2O (0.2 mL) was added TFA (0.8 mL). The 
reaction mixture was stirred for 4 h at 40 oC, and all volatile were evaporated in vacuo. The 
crude mixture was purified by silica gel column chromatography (CHCl3/MeOH 80:20 to 
CHCl3/MeOH/H2O/50% aqueous ammonia 56:42:7:3) to afford 12 (UT-17465) (2.0 mg, 2.2 
mol, 92%): TLC (n-butanol/ethanol/CHCl3/28% aqueous ammonia 4:7:2:7) Rf = 0.55; []
20
D 
+0.246 (c = 0.24, methanol); IR (thin film) max = 3276 (br), 2933, 1675, 1505, 1465, 1271, 1243, 
1199, 1111 cm
−1
; 
1
H NMR (400 MHz, CD3OD) δ 7.84 (d, J = 7.7 Hz, 1H), 7.19 (dd, J = 8.5, 3.3 
Hz, 4H), 7.01 (dd, J = 13.1, 8.6 Hz, 4H), 5.86 (d, J = 7.8 Hz, 1H), 5.73 (d, J = 2.4 Hz, 1H), 5.16 
(s, 1H), 4.54 (tt, J = 7.3, 3.1 Hz, 1H), 4.30 – 4.25 (m, 3H), 4.26 (d, J = 9.2 Hz, 1H), 4.22 – 4.05 
(m, 6H), 3.70 (d, J = 9.2 Hz, 1H), 3.52 – 3.44 (m, 2H), 3.09 (ddt, J = 12.3, 8.6, 4.3 Hz, 2H), 2.91 
– 2.82 (m, 1H), 2.58 – 2.53 (m, 1H), 2.50 (s, 3H), 2.30 (q, J = 6.9 Hz, 2H), 2.15 – 2.08 (m, 2H), 
1.96 – 1.82 (m, 3H), 1.81 – 1.71 (m, 1H), 1.39 – 1.25 (m, 2H); 13C NMR (101 MHz, CD3OD) δ 
175.3, 172.2, 157.6, 152.0, 142.4, 131.3, 129.7 (2C), 123.6 (2C), 118.12 (2C), 118.08 (2C), 111.9, 
92.1, 84.4, 80.3, 78.4, 76.4, 75.4, 74.1 (2C), 71.5, 70.8, 68.3, 43.7, 39.7, 34.5, 31.5 (2C), 24.5; 
HRMS (ESI+) m/z calcd for C40H53F3N7O13 [M + H] 896.3653, found: 896.3640. 
 
 
 
 
 
 
 
 
 
S21 
 
Figure S5. HPLC analysis of 12 (UT-17465). 
 
 
Area % purity: 94.3% 
Conditions: 
column: Phenomenex Kinetex 1.7  XB-C18 100 Å 150 x 2.10 mm column, solvents: 70 : 30 
MeOH : 0.05M NH4HCO3 in water, UV: 254 nm 
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(2S,3S)-3-(((2S,3R,4S,5R)-5-(Aminomethyl)-3,4-dihydroxytetrahydrofuran-2-
yl)oxy)-2-((3-aminopropyl)(methyl)amino)-3-((2S,5R)-5-(2,4-dioxo-3,4-
dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)propanoic acid (1). 
1
H NMR (400 MHz, D2O)  7.79 (d, J = 7.9 Hz, 1H), 5.83 (d, J = 7.8 Hz, 1H), 5.75 (d, J = 2.3 Hz, 
1H), 5.20 (s, 1H), 4.33 (dd, J = 2.3, 5.1 Hz, 1H), 4.28 (dd, J = 2.3, 8.4 Hz, 1H), 4.23 – 4.19 (m, 
2H), 4.16 (dd, J = 2.8, 6.1 Hz, 1H), 4.13 – 4.07 (m, 2H), 3.49 (d, J = 8.3 Hz, 1H), 3.18 (dd, J = 
3.6, 13.7 Hz, 1H), 3.05 – 3.00 (m, 3H), 2.88 – 2.83 (m, 1H), 2.64 – 2.61 (m, 1H), 2.41 (s, 3H), 
1.94 – 1.88 (m, 1H), 1.82 – 1.78 (m, 1H); 13C NMR (101 MHz, D2O)  175.7, 171.4, 155.2, 141.9, 
110.1, 102.5, 91.4, 83.7, 80.8, 78.5, 75.4, 74.2, 71.4, 71.3, 70.0, 52.4, 41.8, 39.0, 38.7, 25.0; 
HRMS (ESI+) m/z calcd for C20H34N5O11 [M + H] 520.2255, found: 520.2262. 
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(2R,3S)-3-(((2S,3R,4S,5R)-5-(Aminomethyl)-3,4-dihydroxytetrahydrofuran-2-
yl)oxy)-2-((3-aminopropyl)(methyl)amino)-3-((2S,5R)-5-(2,4-dioxo-3,4-
dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)propanoic acid (4). 
1
H NMR (400 MHz, D2O) δ 7.83 (d, J = 8.0 Hz, 1H), 5.90 (d, J = 8.3 Hz, 1H), 5.73 (d, J = 2.1 Hz, 
1H), 5.25 (s, 1H), 4.36 (d, J = 7.7 Hz, 1H), 4.28 – 4.19 (m, 2H), 4.18 (d, J = 10.4 Hz, 1H), 4.12 – 
4.06 (m, 2H), 3.45 (d, J = 10.4 Hz, 1H), 3.32 (dd, J = 14.1, 3.7 Hz, 1H), 3.15 (dd, J = 13.9, 5.6 
Hz, 1H), 3.10 – 3.03 (m, 3H), 2.97 – 2.87 (m, 1H), 2.59 – 2.51 (m, 1H), 2.43 (s, 3H), 1.99 – 1.93 
(m, 1H), 1.87 – 1.77 (m, 1H); HRMS (ESI+) m/z calcd for C20H34N5O11 [M + H] 520.2255, 
found: 520.2272. 
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(2S,3R)-3-(((2S,3R,4S,5R)-5-(Aminomethyl)-3,4-dihydroxytetrahydrofuran-2-
yl)oxy)-2-((3-aminopropyl)(methyl)amino)-3-((2S,5R)-5-(2,4-dioxo-3,4-
dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)propanoic acid (5). 
1
H NMR (400 MHz, D2O) δ 7.68 (d, J = 8.2 Hz, 1H), 5.93 (d, J = 8.1 Hz, 1H), 5.77 (d, J = 4.3 Hz, 
1H), 5.33 (s, 1H), 4.50 – 4.44 (m, 3H), 4.20 – 4.11 (m, 3H), 4.06 (dd, J = 5.2, 4.7 Hz, 1H), 3.61 
(d, J = 6.9 Hz, 1H), 3.37 (d, J = 13.2 Hz, 1H), 3.13 (dd, J = 13.2, 8.7 Hz, 1H), 3.06 (t, J = 7.3 Hz, 
2H), 2.84 (dt, J = 13.5, 6.6 Hz, 1H), 2.74 (dt, J = 12.8, 6.7 Hz, 1H), 2.44 (s, 3H), 1.89 (dq, J = 
13.8, 6.6 Hz, 2H); HRMS (ESI+) m/z calcd for C20H34N5O11 [M + H] 520.2255, found: 520.2251. 
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(2R,3R)-3-(((2S,3R,4S,5R)-5-(Aminomethyl)-3,4-dihydroxytetrahydrofuran-2-
yl)oxy)-2-((3-aminopropyl)(methyl)amino)-3-((2S,5R)-5-(2,4-dioxo-3,4-
dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)propanoic acid (6). 
1
H NMR (400 MHz, D2O) δ 7.67 (d, J = 8.0 Hz, 1H), 5.91 (d, J = 8.0 Hz, 1H), 5.78 (d, J = 5.2 Hz, 
1H), 5.31 (s, 1H), 4.49 – 4.44 (m, 1H), 4.43 (t, J = 5.3 Hz, 2H), 4.16 – 4.07 (m, 3H), 4.05 (t, J = 
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5.3 Hz, 1H), 3.54 (d, J = 7.3 Hz, 1H), 3.23 (dd, J = 13.3, 3.0 Hz, 1H), 3.10 – 2.98 (m, 3H), 2.80 
(dt, J = 13.3, 6.7 Hz, 1H), 2.67 (dt, J = 13.3, 6.9 Hz, 1H), 2.38 (s, 3H), 1.86 (dq, J = 13.9, 7.1 Hz, 
2H); HRMS (ESI+) m/z calcd for C20H34N5O11 [M + H] 520.2255, found: 520.2247. 
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(2S,3S)-3-(((2S,3R,4S,5R)-5-(Aminomethyl)-3,4-dihydroxytetrahydrofuran-2-
yl)oxy)-2-((3-aminopropyl)(methyl)amino)-3-((2S,5R)-5-(2,4-dioxo-3,4-
dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)propanamide (7). 
1
H NMR (400 MHz, D2O) δ 7.83 (d, J = 8.1 Hz, 1H), 5.91 (d, J = 8.0 Hz, 1H), 5.72 (s, 1H), 5.27 
(s, 1H), 4.44 – 4.37 (m, 1H), 4.32 – 4.25 (m, 2H), 4.23 (t, J = 6.5 Hz, 1H), 4.20 – 4.14 (m, 1H), 
4.11 (d, J = 8.2 Hz, 1H), 3.68 (dd, J = 16.3, 8.1 Hz, 1H), 3.43 (d, J = 14.0 Hz, 1H), 3.26 (dd, J = 
13.6, 5.2 Hz, 2H), 3.07 (t, J = 7.3 Hz, 2H), 3.03 – 2.95 (m, 1H), 2.64 – 2.56 (m, 1H), 2.50 (s, 3H), 
2.04 – 1.94 (m, 1H), 1.88 – 1.79 (m, 1H); HRMS (ESI+) m/z calcd for C20H35N6O10 [M + H] 
519.2415, found: 519.2432. 
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(2S,3S)-3-(((2S,3R,4S,5R)-5-(Aminomethyl)-3,4-dihydroxytetrahydrofuran-2-
yl)oxy)-2-((3-aminopropyl)amino)-3-((2S,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-
1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)propanamide (8). 1H NMR (400 MHz, 
D2O) δ 7.78 (d, J = 8.1 Hz, 1H), 5.89 (d, J = 7.8 Hz, 1H), 5.78 (d, J = 3.1 Hz, 1H), 5.22 (s, 1H), 
4.40 (dd, J = 5.5, 3.2 Hz, 1H), 4.29 (t, J = 6.3 Hz, 1H), 4.22 (dd, J = 6.8, 5.1 Hz, 1H), 4.18 (t, J = 
4.5 Hz, 1H), 4.16 – 4.08 (m, 3H), 3.59 (d, J = 3.8 Hz, 1H), 3.28 (d, J = 12.6 Hz, 1H), 3.11 – 3.02 
(m, 3H), 2.77 (dt, J = 12.8, 6.8 Hz, 1H), 2.64 (dt, J = 12.7, 7.0 Hz, 1H), 1.83 (quin, J = 7.1 Hz, 
2H); HRMS (ESI+) m/z calcd for C19H33N6O10 [M + H] 505.2258, found: 505.2277. 
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Figure S6. Conformational analyses of 9-12.
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4.28 (d, H-5', J5'-6' = 9.3 Hz, 1H)
3.61 (d, H-6', J6'-5' = 9.4 Hz, 1H)
Calculated dihedral angle H5'-C-C-H6': 192 
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Calculated dihedral angle H5'-C-C-H6': 188  
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 3.44 (d, H-6', J6'-5' = 8.8 Hz, 1H)
Calculated dihedral angle H5'-C-C-H6': 207  
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4.26 (d, H-5', J5'-6' = 9.2 Hz, 1H)
3.70 (d, H-6', J6'-5' = 9.2 Hz, 1H)
Calculated dihedral angle H5'-C-C-H6': 196 
 
 
 
Determination of water-solubility of 11 (UT-17460). 
 
A suspension of 11 (3.0 mg) in H2O (50 L) was stirred for 24h, and the precipitate was 
separated by centrifugation at 10,000 x g for 5 min. The upper solution (1 L) was 
analyzed via C18 reverse-phase HPLC [column: Kinetex (100 Å, 5 m, 250 x 4.60 mm), 
solvents: 75:25 MeOH : 0.05M NH4HCO3 aq., flow rate: 0.5 mL/min, UV: 254 nm, 
retention time: 13.2 min]. The area of the peak for 11 was quantified. The concentrations 
were determined via the HPLC intensity-concentration curves.
7,8,9
 
 
Figure S7. Concentration of 11.  
 
concentration (mg/mL) 0.35 0.6 1.15 5.77 12.25 22.36 
intensity 662186 1559793 3197580 15843516 33184625 60023983 
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Table S1. Representative structures of a library of FR-900493 analogs.  
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a
WecA: at 25 M.; bMraY assay: at 25 M. cC. difficile ATCC43596: 50 g/mL. 
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Bacterial strains and growth of bacteria 
 
Mycobacterium smegmatis (ATCC 607), Klebsiella pneumoniae (ATCC 8047), 
Pseudomonas aeruginosa (ATCC 27853), Acinetobacter baumannii (ATCC 19606), 
Staphylococcus aureus (BAA-1683), Clostridium difficile (ATCC 43596), Enterococcus 
faecium (ATCC 349), Fusobacterium periodontium ATCC 33693), Bacteroides fragilis 
(ATCC 25285), Streptococcus pneumoniae (ATCC 6301), Bacillus subtilis (ATCC 6051), 
Clostridium perfringens (ATCC 13124), Lactobacillus casei (ATCC 393), Lactobacillus 
acidophilus (ATCC 4356), and E. coli (ATCC 10798) were obtained from American 
Type Culture Collection (ATCC). A single colony of Mycobacterium smegmatis was 
obtained on Difco Middlebrook 7H10 nutrient agar enriched with with albumin, dextrose, 
and catalase (ADC). Single colonies of P. aeruginosa, K. pneumoniae, A. baumannii, 
S.aureus, E. faecium and E. coli were grown on tryptic soy agar for 24 h at 37
o
C in a 
static incubator and cultured in tryptic soy broth until log phase to be an optical density 
(OD) of 0.2-0.5. The OD was monitored at 600 and 570 nm using a 96-well microplate 
reader. A single colony of C. difficile was obtained on a BHI agar plate and incubated at 
37 
o
C under anaerobic conditions for 48 h (Gas: 10% hydrogen, 5% carbon dioxide and 
85% nitrogen mixture was used. Chambers: Plas Labs™ Model 855 Anaerobic Chambers 
was used.). The other bacteria were cultured in the recommended conditions by ATCC. 
 
 
 
MIC assays 
Minimum inhibitory concentrations were determined by broth dilution microplate alamar 
blue assay or by OD measurement. All compounds were stored in DMSO or PEG400-
water (1/1) (1 mg/100 L concentration). This concentration was used as the stock 
solution for all MIC studies. Each compound from stock solution was placed in the first 
well of a sterile 96 well plate and a serial dilution was conducted with the culturing broth 
(total volume of 10 L). The bacterial suspension at log phase (190 L) was added to 
each well (total volume of 200 L). M. smegmatis, P. aeruginosa, K. pneumoniae, A. 
baumannii, S. aureus, E. faecium, E. coli, and the aerobic bacteria were incubated for 24 
h at 37 
o
C. Clostridium spp. were incubated for 48 h at 37 
o
C under anaerobic condition. 
20 L of resazurin (0.02%) was added to each well and incubated for 4 h for 
Mycobacterium spp., and 1 h for the other bacteria (National Committee for Clinical 
Laboratory Standards (NCCLS) method (pink = growth, blue = no visible growth)).The 
OD measurements were performed for all experiments prior to colorimetric The 
anaerobic bacteria were applied to a microplate reader. The MIC values were determined 
according to the colorimetric assays using resazurin. The absorbance of each well was 
also measured at 570 and 600 nm via UV-Vis. The MIC values of the anaerobic bacteria 
(Clostridium spp.) were determined via OD600 and OD570. If necessary, CFU method was 
applied to confirm bactericidal activity.  
 
 
 
C. difficile spore preparation.  
C. difficile (ATCC 43596) was inoculated on a BHI agar plate and incubated at 37 
o
C 
under anaerobic condition for 14 days. The spores were harvested by flooding plates with 
deionized water and gently scrapping the bacterial lawns. The harvested cells were 
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pelleted via centrifugation at 4,700 x g for 20 min. and washed with deionized water (x3). 
The obtained bacterial pellet was suspended sterile water and the vegetative forms of C. 
difficile were killed upon heating at 50 
0
C for 30 min.,
10,11
 and the bacteria were washed 
with sterile water (x3). The washed pellet was resuspended in sterile water (10 mL) and 
layered on top of sterile 50% sucrose (in water). The gradient was centrifuged at 3,200 x 
g for 20 min. The 50% sucrose bed was separated and the spore pellet was washed with 
sterile water (x5). All cells appeared a bright greenish color upon staining with malachite 
green oxalate. The prepared spores were suspended (OD600 ~0.2) in sterile distilled water 
at 4 
o
C. 
 
Figure S8. Microscopic analyses of C. difficile spores (x100). 
 
 
 
 
 
Spore viability assays. 
A solution of test compound was added to a suspension containing C. difficile spores (2 x 
10
5
 ml
-1
), and the mixture was incubated at 37 
o
C for 24 h. The spore suspension treated 
with test compound was centrifuged (4,700 x g) and the pellet was washed with sterile 
distilled water, and plated on a BHI agar containing 0.1% sodium taurocholate (a 
germination agent) and incubated at 37 
o
C for 48h under anaerobic conations. The 
resulting colonies were counted. Separately, the C. difficile spore suspension treated with 
test molecules 24 h was cultured in a BHI medium containing 0.1% sodium taurocholate. 
After 48 h, variability of the C. difficile spores was quantitated by the OD600 value. 
 
Table S2. MIC (g/mL) against C. difficile (ATCC 43596) 
Vancomycin:   2.50 
Metronidazole: 0.39 
Linezolid:  1.56 
UT-17415 (9):  25.0 
UT-17455 (10): 12.5 
UT-17460 (11): 3.25 
UT-17465 (12): 50.0 
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 No drug Vancomycin
1
 Metronidazole
1
 Linezolid
1
 
CFU (x10
6
/mL) 1250 1150 1100 1200 
OD600 0.4-0.6 0.45 0.48 0.49 
1 
X 5 MIC was used 
 
 UT-17415 (9)
2
 UT-17455 (10)
2
 UT-17460 (11)
2
 UT-17465 (12)
2
 
CFU 0 0 0 0 
OD600 0.02 0.02 0.02 0.02 
2 
X 2 MIC was used 
 
Figure S9. Growth of C. difficile spores treated with drugs.  
 
 
 
 
 
 
 
 
 
 
 
The C. difficile spores (OD600 ~0.2) were treated with 2X MIC (9, 10, 11, and 12) or 5X MIC (vancomycin, 
metronidazole, and linezolid). After 24 h, portion (100 L) of each spore suspension was cultured in a BHI 
medium containing 0.1% sodium taurocholate for 48 h.  
 
 
 
Preparation of membrane fraction P-60 containing MraY and WecA 
 
M. smegmatis cells were harvested by centrifugation (4700 rpm) at 4 
o
C followed by 
washing with 0.9% saline solution (thrice), and approximately 5 g of pellet (wet weight) 
was collected. The washed cell pellets were suspended in homogenization buffer 
(containing 50 mM MOPS [pH = 8.0], 10 mM MgCl2, and 5 mM 2-mercaptoethanol) and 
disrupted by probe sonication on ice (10 cycles of 60 s on and 90 s off). The resulting 
suspension was centrifuged at 1,000 x g for 10 min at 4 
o
C to remove unbroken cells. The 
supernatant was centrifuged at 15,000 x g for 40 min at 4 
o
C (2 or 3 times). All pellets in 
each tube were pooled, and a second sonication was performed (10 cycles of 60 s on and 
90 s off). The lysate was centrifuged once at 15,000 xg for 1 h, and the supernatant was 
subjected to ultracentrifugation at 60,000 x g for 1 h at 4 
o
C. The supernatant was 
discarded, and the membrane fraction containing MraY enzyme (P-60) was suspended in 
the Tris-HCl buffer (pH = 7.5) containing 2-mercaptoethanol. Total protein 
concentrations were approximately 8 to 10 mg/mL. Aliquots were stored in Eppendorf 
tubes at -80 
o
C. Similarly, the membrane fractions containing WecA enzyme (P-60) were 
prepared from E. coli. 
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Expression and purification of HyMraY  
The gene mraY of Hydrogenivirga spp. 128-5-R1-1 was cloned with a N-terminal His6 tag into a 
pET22b vector. The plasmid was transformed and expressed in E. coli NiCo21(DE3) pLEMO 
competent cells. The proteins were purified using a nickel, cation exchange, and size exclusion 
chromatography. The final storage buffer was 20 mM HEPES pH 7.5, 100 mM NaCl, 10% 
glycerol, 5 mM βME, 0.15% DM.  
 
 
 
Expression and purification of MjAglH  
The gene mj1113 of Methanocaldococcus jannaschii DSM 2661 was cloned with a N-terminal 
His9 tag into a pET33b-derived vector. The plasmid was transformed and expressed in E. coli 
NiCo21(DE3) pLEMO competent cells. The proteins were purified using cobalt and size 
exclusion chromatography. The final storage buffer was 20 mM Tris-HCl, pH 7.5, 100 mM NaCl, 
5% glycerol, 5 mM βME, 0.15% DM.  
 
 
 
MraY assay. 
MraY assay substrates, Park’s nucleotide-Nε-C6-dansyl, neryl phosphate, were 
chemically synthesized according to the reported procedures. 
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Park’s nucleotide-Nε-C6-dansyl (2 mM stock solution, 1.88 μL), MgCl2 (0.5 M, 5 μL), 
KCl (2 M, 5 μL), Triton X-100 (0.5%, 5.63 μL), Tris buffer (pH 8.0, 50 mM), neryl 
phosphate (0.1 M, 2.25 μL), and inhibitor molecue (0 - 100 g/mL in Tris buffer) were 
placed in a 500 μL Eppendorf tube. To a stirred reaction mixture, P-60 (10μL) was added 
(total volume of reaction mixture: 50 μL adjust with Tris buffer). The reaction mixture 
was incubated for 2 h at room temperature (26 
o
C) and quenched with CHCl3 (100μL). 
Two phases were mixed via vortex and centrifuged at 25,000 xg for 10 min. The upper 
aqueous phase was assayed via reverse-phase HPLC. The water phase (10 μL) was 
injected into HPLC (solvent: CH3CN/0.05 M aq. NH4HCO3 = 25:75; UV: 350 nm; flow 
rate: 0.5 mL/min; column: Kinetex 5μm C8, 100 A, 150 x 4.60 mm), and the area of the 
peak for lipid I-neryl derivative was quantified to obtain the IC50 value. The IC50 values 
were calculated from plots of the percentage product inhibition versus the inhibitor 
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concentration. 
 
Figure S10. 
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WecA assay. 
WecA assay substrate, UDP-Glucosamine-C6-FITC was chemically synthesized 
according to the reported procedures. 
13
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UDP-Glucosamine-C6-FITC (2 mM stock solution, 0.56 L), MgCl2 (0.5 M, 4 L), -
mercaptoethanol (50 mM, 5 L), CHAPS (5%, 11.25 L), Tris buffer (pH 8.0, 50 mM), 
undecaprenyl phosphate (4 mM, 1.4 L), and inhibitor molecue (0 - 100 g/mL in Tris 
buffer) were place in a 500L Eppendorf tube. To a stirred reaction mixture, P-60 (10 
L) was added (total volume of reaction mixture: 50 L adjust with Tris buffer). The 
reaction mixture was incubated for 4 h at 37 
o
C and quenched with n-butanol (150 L). 
Two phases were mixed via vortex and centrifuged at 10,000 xg for 3 min. The upper 
organic phase was assayed via reverse-phase HPLC. The organic phase (30 L) was 
injected into HPLC (solvent: gradient elution of 85:15 to 95:5 MeOH/0.05 M aq. 
NH4HCO3; UV: 485 nm; flow rate: 0.5 ml/ min; column: Kinetex 5 m C8, 100 Å, 150 x 
4.60 mm), and the area of the peak for C55-P-P-glucosamine-C6-FITC was quantified to 
obtain the IC50 value. The IC50 values were calculated from plots of the percentage 
product inhibition versus the inhibitor concentration. 
 
Figure S11. 
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AglH assay. 
AglH assays were performed as the procedure described for WecA assays, but used 
MjAglH and -dihydroundecaprenyl phosphate instead of WecA and undecaprenyl 
phosphate.  
 
Figure S12. 
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Determination of cytotoxicity in Vero Cells 
 
Selected molecules were tested for cytotoxicity (IC50) in Vero cells via a MTT 
colorimetric assay. Vero cell line was cultured in Complete eagle`s minimum essential 
growth medium (EMEM) containing L-glutamine, sodium pyruvate, minimum essential 
amino acids, penicillin-streptomycin and 10% fetal bovine serum. Inoculating number of 
cells were 400,000 cells/mL and a final 40,000 cells/well. After 72h of exposure of 
molecules to this cell line at concentrations ranging from 0.78 to 200 g/mL, the culture 
medium was changed to complete EMEM without phenol red before addition of yellow 
tetrazolium dye; MTT. Viability was assessed on the basis of cellular conversion of MTT 
into a purple formazan product. The absorbance of the colored formazan product was 
measured at 570 nm by BioTek Synergy HT Spectrophotometer. Linearity of the MTT 
response to the cell number was determined. 
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Figure S13. MTT response vs population of Vero cells. 
 
 
 
 
 
Figure S14. Cytotoxicity of UT-17455 against Vero cells. 
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Figure S15. Cytotoxicity of UT-17460 against Vero cells. 
 
 
 
 
 
Figure S16. Cytotoxicity of tunicamycin against Vero cells. 
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Table S3. Cytotoxicity of UT-17460 against Caco-2, HepG2 and Vero cells. 
 
   HepG2 
Human hepatocyte 
carcinoma 
Caco-2 
Human colon 
adenocarcinoma 
Vero 
Green monkey kidney 
epithelial cells 
 UT-17460  >60.0 >60.0 65.0 
 Tunicamycin  0.19 0.95 0.12 
 Taxol  2.33 5.50 4.67 
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